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Mood disorders are chronic and debilitating psychiatric diseases that affect 450 million 
people worldwide. Despite their overwhelming prevalence, the etiology and 
pathophysiology of these disorders are poorly understood. As a result, mood disorders are 
diagnosed by symptom presentation, not disease processes. Furthermore, our incomplete 
understanding of the biological underpinnings of these disorders is a major impediment to 
the development of effective treatments.   
Animal models offer a tractable means of examining the molecular and cellular 
processes that contribute to the pathogenesis of psychiatric disorders. Chronic social defeat 
(SD) stress is a novel ethologically-relevant mouse model of affective psychopathology. 
Like all animal models, face, construct, and predictive validity must first be established for 
SD before findings in this model can be extrapolated to the clinic. Though the depressive-
like and anxious phenotypes induced by SD are well-established, cognitive symptoms have 
yet to be validated. As cognitive impairment is a significant but understudied core 
symptom of affective disorders, we sought to determine if SD would recapitulate this 
dimension of psychopathology.  
First we confirmed that SD induced depressive-like and anxious behavior 
(ethological validity), as well as decreased adult neurogenesis in the dentate gyrus of the 
hippocampus—an established correlate of depressive behavior (biomarker validity), in our 
experimental mouse strain. We then tested mice in two learning paradigms: 1-shock 
 
contextual fear conditioning (CFC) and novel object recognition (NOR). SD mice were 
significantly impaired in CFC fear memory recall, as well as in NOR. Having identified a 
robust cognitive impairment in 1-shock CFC, we sought to locate a neural correlate of this 
deficit. As both 1-shock CFC and NOR are hippocampus-dependent tasks, and knowing that 
SD alters hippocampal architecture by decreasing adult hippocampal neurogenesis, we 
chose to examine cellular activity patterns in the dentate gyrus and its downstream target, 
CA3. We found that impaired fear expression during context re-exposure correlated with 
decreased reactivation in CA3. 
Having confirmed SD as a viable model for the study of affective disorders, we then 
used this model to explore the antidepressant potential of ketamine. Classical 
antidepressants have a delayed onset of therapeutic efficacy of approximately four to six 
weeks. Ketamine, an NMDA receptor antagonist, has recently been identified as a rapid-
acting antidepressant in humans. In order to explore ketamine’s antidepressant mechanism 
of action, mouse models of ketamine administration need to be established and optimized. 
Though several groups have begun to investigate the antidepressant effect of ketamine in 
mice, dose, strain, and behavioral paradigms have yet to be systematically titrated. We 
found only a modest antidepressant effect of ketamine following SD. In conjunction with 
other murine ketamine studies, this modest effect argues for a more rigorous optimization 
of ketamine administration paradigms in mice. 
We next sought to determine if ketamine could protect against the induction of 
psychopathology. Psychiatric disorders are not traditionally approached from a preventive 
perspective. This is in part because the etiology of these disorders remains largely 
unknown. It is known, however, that stress can precipitate affective disorders such as 
 
major depressive disorder and post-traumatic stress disorder, as well as trigger 
symptomatic episodes in patients with prior psychiatric diagnoses. However, stress does 
not ubiquitously induce psychopathology in all exposed individuals. Stress resilience, the 
capability to withstand stress without developing an affective disorder, varies across 
individuals. Using the SD model of chronic stress, we sought to determine if ketamine could 
enhance stress resilience, thereby protecting mice from the depressive-like sequelae of 
chronic stress exposure. 
We found that a single subanesthetic dose of ketamine was protective against 
stress-induced depressive-like behavior for at least three weeks following administration. 
The drug was given a week prior to SD and, as ketamine has a half-life of only a few hours, 
was fully washed out by the commencement of the stress paradigm. This finding 
demonstrates that ketamine induces an actively self-maintaining form of resilience. Though 
we observed a protective effect of ketamine out to three weeks, it is possible that this effect 
persists even longer in duration. If this prophylactic effect translates to humans, ketamine 
could potentially be used in at-risk populations, such as active-duty soldiers, to inoculate 
against stress-induced psychopathology. 
In summary, this thesis establishes chronic social defeat stress as a valid model of 
the cognitive behavioral symptoms of affective disorders, as well as identifies decreased 
reactivation in CA3 as a cellular correlate of stress-induced cognitive impairment. 
Furthermore, we find that ketamine has a modest antidepressant effect when administered 
following two weeks of defeat stress. Most importantly, however, we show that a single 
subanesthetic dose of ketamine can induce robust, long-lasting, self-maintaining stress 
resilience. The work in this thesis establishes prophylactic ketamine as a novel model of 
 
stress resilience and identifies ketamine as the first clinic-ready pharmaceutical with the 
potential to prevent psychiatric disorders. 
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Mood disorders, or affective disorders, are debilitating psychiatric diseases that affect 20-
30% of all Americans at some point in their lives (Kessler et al., 2005). Worldwide, an 
estimated 350 million people suffer from major depressive disorder (MDD) alone, with 
approximately 1 million deaths per year resulting from associated suicide (WHO, 2012). 
Meanwhile, post-traumatic stress disorder (PTSD), another affective disorder, afflicts one 
in five active combat soldiers (Tanielian and Rand Corporation, 2008). Yet, despite this 
overwhelming prevalence, only 20% of individuals suffering from affective disorders 
receive even minimally adequate treatment (Wang et al., 2005).  
The diagnostic criteria for anxiety and depressive disorders like MDD and PTSD are 
based on behavioral symptomology. The major symptoms of these disorders cluster into 
different dimensions. The primary dimensions are depressive behavior, anhedonia, anxiety, 
cognitive impairment, and peripheral changes (e.g., metabolic disturbances, altered 
immune function, hypothalamic-pituitary-adrenal (HPA)-axis dysregulation), though not 
every dimension is currently used diagnostically (APA, 2013; Kiecolt-Glaser and Glaser, 
2002; Miller, 1998; Papakostas, 2014). Moreover, these clusters do not necessarily present 
in every disorder, or for that matter in every patient within a disorder. Because these 
disorders are diagnosed by symptoms, the diagnostic classification of “MDD,” for example, 
is actually a heterogeneous assortment of subset conditions grouped together because they 
share a common clinical presentation.  
In general, affective disorders are chronic and episodic. Classical treatment options 
for these disorders are limited in efficacy and patient compliance (due to adverse side 
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effects). Novel advances in treatment approaches are hindered by the fact that the etiology 
and pathophysiology of these disorders are poorly understood. Understanding the 
biological mechanisms underlying affective disorders is essential to create better 
therapeutics.  
 
Stress as a risk factor for affective disorders: resilience vs. susceptibility 
Genetic predisposition, changes in HPA-axis function, decreased adult hippocampal 
neurogenesis, and dysregulated neurotransmitter systems (5-HT, dopamine, glutamate, 
etc.) have all been implicated as risk factors for mood disorders (Hasler, 2010). The 
relationship between these biological factors and the emergence of psychopathology 
remains to be elucidated. What is known, however, is that psychological stress can trigger 
symptomatic episodes in patients with pre-existing diagnoses. Stress can even induce de 
novo psychopathology in previously healthy individuals, and this pathology can persist 
even after the stressor resolves. Interestingly, not everyone exposed to the same stress 
develops a psychiatric disorder. Much work has been done recently exploring the 
mechanisms underlying different susceptibilities to stress-induced psychopathology. The 
ability to actively cope with stress exposure, maintain homeostasis, and not develop a 
subsequent psychiatric disorder is called “stress resilience.” 
 Recent work has demonstrated that stress resilience is an active process and not 
just the absence of susceptibility risk factors (Russo et al., 2012). Though the mechanisms 
underlying stress resilience have yet to be fully elucidated, several factors have been 
identified as putatively involved. For example, the steroid hormones 
dehydroepiandrosterone (DHEA) and testosterone have both been correlatively implicated 
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as pro-resilient in humans (Charney, 2004; Herrera-Perez et al., 2012; Taylor et al., 2012; 
Yehuda et al., 2006). At a circuit level, the infralimbic and prelimbic cortices have been 
implicated in resilience and susceptibility, respectively (Lehmann and Herkenham, 2011; 
Vialou et al., 2010b), as have regions such as the ventral tegmental area and the nucleus 
accumbens (Chaudhury et al., 2013; Vialou et al., 2010b). From the perspective of 
enhancement, which is the ultimate clinical goal, ∆FosB overexpression and optogenetic 
stimulation have been used successfully in mice to increase stress resilience (Chaudhury et 
al., 2013; Donahue et al., 2014; Vialou et al., 2014; Vialou et al., 2010b). These approaches, 
however, have limited translatability to humans. 
If we were able to enhance resilience, either by targeting these pathways or novel 
as-of-yet unidentified pathways, we could potentially prevent the induction of stress-
induced psychiatric diseases. Though our limited understanding of the mechanisms 
underlying stress resilience has not yet allowed for the production of rationally designed 
drugs to this end, it is possible that agents already in clinical use may have resilience-
enhancing properties that have yet to be identified.  
 
Recent advances in treatment: ketamine 
The discovery of selective serotonin reuptake inhibitors (SSRIs) in the 1970s is by and 
large heralded as the last significant advance in the treatment of psychiatric disorders. 
Similar to earlier antidepressants, the SSRIs have a delayed onset of therapeutic efficacy of 
approximately four to six weeks (Quitkin et al., 1996) (Table 1.1). This delay in therapeutic 
efficacy, which characterizes all the widely used classes of antidepressants, is an obvious 
barrier to rapid treatment and is particularly suboptimal in the case of suicidal patients. 
 5
The SSRIs are, however, still a significant advancement in safety and tolerability over the 
older antidepressant drugs, the tricyclics and MOA-inhibitors (Lieberman, 2003). But even 
so, a quarter of patients discontinue SSRI use due to adverse effects (Demyttenaere et al., 
2001; Hu et al., 2004). In addition to complaints of sexual dysfunction, weight gain, and 
sleep disturbances (Kelly et al., 2008), the SSRIs can also induce suicidal ideation (Jick et al., 
2004). Beyond their undesirable side effect profiles, the classical antidepressants are 
ineffective in a large subset of treatment-resistant patients (Holtzheimer and Mayberg, 
2012) and can loose efficacy over time even in patients who initially respond well (Byrne 
and Rothschild, 1998). As a result, additional avenues of treatment—such as exercise, light 
therapy, electroconvulsive therapy, and deep brain stimulation—are being pursued in the 
clinic and explored at the bench.  
Recently, some compounds have been shown to have rapid-onset antidepressant 
effects (Berman et al., 2000; Mathew et al., 2008). Ketamine, a non-competitive N-methyl-
D-aspartate (NMDA) receptor antagonist, has recently been found to be a rapid-acting 
antidepressant in humans (Mathew et al., 2008). With therapeutic response observed as 
rapidly as 2 hours following a single dose (Zarate et al., 2006), ketamine could potentially 
fill the 4-6 week efficacy gap that has plagued patients and practitioners since the 
discovery of tricyclic antidepressants in the 1950s (Lieberman, 2003) (Table 1.1). 
Additionally, a single subanesthetic dose of ketamine can have long-lasting effects (Zarate 
et al., 2006)—persisting for days to weeks—and has also been found to induce remission in 
many previously treatment-resistant cases (Murrough et al., 2013b). Though in many ways 
ketamine offers a clinic-ready alternative to the classical antidepressants, it is far from an 
ideal drug. Ketamine has undesirable side effects, including dissociative hallucinations, and 
 
a significant potential for abuse 
myriad of different biological systems 
more targeted (i.e., cleaner) and safer rapid
mechanisms by which ketamine exerts its antidep
Moreover, exhaustive work has been done exploring the cellular and molecular 
changes induced by the classical antidepressants in an attempt to understand the 
molecular mechanisms underlying affectiv
onset of efficacy and works through different receptors than previously studied drugs, it 
offers a new tool to explore the mechanism underlying depression and anxiety. 
 
Table 1.1. Comparison of efficacy and side 
SSRIs and the novel rapid-acting antidepressant
 
Animal models of stress-induced psychiatric 
As the study of the neuronal basis of depressive and anxious b
invasive, much of the work is done in animal models. 
animal models must fulfill several 
types of validity that have become the standa
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(Jolly and McLean, 2012). Ketamine also modulates a 
(Jolly and McLean, 2012). Thus, in order to 
-acting drugs, it is essential that we identify
ressant action.  
e disorders. Because ketamine has such a rapid 
effect profiles for the classical antidepressant 
 ketamine. 
disorders 
ehavior is by necessity 
To be considered clinically
validity criteria. In 1984, Willner first proposed the three 







psychiatric disorders: face, construct, and predictive validity (Willner, 1984). Face validity 
refers to the apparent phenomenological reasonableness of a given model; in other words, 
the model subjectively “seems like” it measures what it is supposed to measure. Face 
validity relies predominantly on the rules of common sense and is the least strict of the 
types of validity. Belzung and Lemoine propose observable behavioral (ethological validity) 
and physiological (biomarker validity) phenotypes as the two core subcategories of face 
validity for animal models of psychiatric disorders (Belzung and Lemoine, 2011). Beyond 
“seems like,” construct validity requires that a model have an established empirical and 
theoretical relationship to what it is testing. Construct validity is a measure of the extent to 
which a test actually measures what it claims to. For example, surgery often increases 
swimming in FST (unpublished results). On face, it appears that surgery decreases 
depressive-like behavior. In reality, surgerized (i.e., partially shaved) mice swim more 
because they are less buoyant following disruption of coat integrity. FST lacks construct 
validity in these conditions. In another example, a disease model that recapitulates the 
etiology of a disorder has greater construct validity than one that induces the same 
symptoms by artificial means (e.g., an insulin-resistance model of edema has greater 
construct validity for the study of diabetic edema than does formalin-induced edema). 
Predictive validity refers to the usefulness of a test or model to predict future performance. 
Willner’s predictive validity specifically refers to the ability of a test to predict future 
therapeutic efficacy of a given treatment (pharmaceuticals, electroconvulsive shock 
therapy, etc.). 
Particularly in terms of construct validity, modeling psychiatric disorders—diseases 
for which the etiology and pathophysiology remain obscured—has posed an ongoing 
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challenge to researchers. Advantageously, animal models that rely on stressors to induce 
psychopathology have clear etiological relevance (i.e., construct validity) to at least the 
subset of affective disorders that are precipitated by stress. The chronic unpredictable mild 
stress (CMS) model was developed in 1981 by Katz et al. (Katz, 1981; Katz and Hersh, 
1981; Katz et al., 1981) and further optimized in subsequent years by Willner et al. and 
others (Willner, 1984, 1997). In the CMS model, rodents are exposed to a series of varied, 
unpredictable mild stressors, such as brief periods of restraint, overnight illumination, food 
deprivation, etc. (Willner, 1997). This model has been shown to have face, construct, and 
predictive validity (Willner, 1997). Originally developed in rats, the model has also 
subsequently been adapted to mice. The stressors used are artificial, however, and unlikely 
to be stressors mice would encounter outside of a lab environment.  
In part to address this issue, Teskey et al. first explored the possibility that social 
conflict and defeat could be used as a naturalistic stressor (Teskey et al., 1984). As the 
majority of stressors that induce clinical psychopathology in humans are social ones 
(Brown and Prudo, 1981), using social defeat (SD) stress offers an advantage over CMS 
stressors. Adapted from the original Teskey model, multiple research groups have begun 
using repeated social defeats in lieu of artificial stressors (Berton et al., 2006; Kovalenko et 
al., 2014; Kudryavtseva et al., 1991; Lehmann et al., 2013a; Schloesser et al., 2010).  
Chronic social defeat stress is a novel, etiologically relevant animal model that 
allows for the study of depressive behavior in mice. This model, in which experimental 
mice are co-housed with dominant aggressor mice and subjected to chronic social defeat, 
reliably yields an anxious and depressive phenotype and is unique in that it models the 
social component of depression. As different types of stressors cause different 
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physiological and affective changes (Blanchard et al., 2001), and as the predominance of 
stress-induced depression is caused by psychosocial stress, chronic social defeat (SD) 
stress appears to be a more valid model of clinical depression than previous animal models 
of depression. Though the pathogenic, i.e., triggering, construct validity (Belzung and 
Lemoine, 2011) of the SD model is self-evident, in terms of face validity, to what extent this 
model recapitulates all of the symptom dimensions of stress-induced psychopathology still 
remains to be characterized. Cognitive deficits, for example, are essentially unexamined in 
this model. As argued by Willner and others, a psychiatric model is only as valid as its 
recapitulation of the symptoms of the disorder it is modeling (Geyer and Markou, 1995; 
McKinney and Bunney, 1969; Willner and Mitchell, 2002). Thus, as cognitive impairment is 
one of the cardinal symptoms of affective disorders, it is essential that cognition function be 
examined following SD to determine the extent of face validity of this model. 
 
Operationalization of behavior in mice 
Numerous tests have been developed in order to quantify behavioral states in mice. Some 
tests look at several dimensions of behavior simultaneously. The tests used in this thesis 
are organized here by relevance to different dimensions of symptomology in psychiatric 
disorders. These behavioral tests are subject to the same general validity requirements 
described in the previous section. 
Anxiety tests utilized include the Open Field Test (OF), Novelty Suppressed Feeding 
(NSF), and Elevated Plus Maze (EPM). In the OF, mice are placed in a novel open chamber 
and allowed to explore. In general, mice prefer to stay close to the walls of the open field 
chamber, a phenomenon known as thigmotaxis, as opposed to venturing into the more 
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anxiogenic exposed center space (Haller and Alicki, 2012; Simon et al., 1994). Willingness 
to venture into the center is used as a measure of anxious behavior, with greater time in the 
center associated with lower levels of anxiety (Haller and Alicki, 2012; Simon et al., 1994). 
Open field can also be used to assess basic locomotion and baseline activity. NSF is an 
extension of OF, in which the hunger drive is used in lieu of exploratory drive. As hunger is 
considered a stronger motivator than basic exploration, NSF taps into a different range of 
anxiety behaviors than OF. In NSF, food-deprived mice are placed into a brightly lit, 
unfamiliar chamber with a food pellet placed in the center (Denny et al., 2012; Wang et al., 
2008). Latency to feed is used as a measure of anxiety; longer latencies are indicative of 
higher anxiety. This test can also be used to measure differences in hunger and metabolism. 
The EPM is an elevated maze consisting of two open and two closed arms. EPM is similar to 
OF in that willingness to explore an anxiogenic exposed area, i.e., the open arms, is 
measured relative to time spent and distance traveled in the less anxiogenic closed arms 
(Saxe et al., 2006). Relative preference for the closed arms is considered a measure of 
anxiety. 
The depressive tests employed in this thesis include the Forced Swim Test (FST), 
Tail Suspension Test (TST), and stress-induced hypophagia. The FST is one of the most 
commonly used tests of depressive-like behavior, primarily because of its predictive 
validity for antidepressant drug efficacy (Carlezon et al., 2002; Castagne et al., 2009; Petit-
Demouliere et al., 2005). In FST, mice are placed in water in a cylindrical chamber from 
which they cannot escape. Passive floating, as opposed to swimming or climbing, is 
considered a measure of depressive-like behavior (Petit-Demouliere et al., 2005; Porsolt et 
al., 1978a; Porsolt et al., 1978b). The TST is based on the same principles underlying forced 
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swim, and is sometimes referred to as a ‘dry’ FST (Castagne et al., 2011). In tail suspension, 
mice are held upside-down by their tails and struggling activity is measured. Immobility is 
reported as a measure of depressive-like behavior. Stress-induced hypophagia differs 
significantly from FST and TST in the nature of its validity. Stress-induced hypophagia is a 
primarily construct validity-driven test based on the established phenomenon that acute 
stress can induce hypophagia (Maniscalco et al., 2012). Hypophagia can be measured by 
either pellet consumption or weight loss. 
As cognition is less commonly assessed in psychiatric models, which tests are most 
relevant has yet to be determined. Some of the predominant cognitive symptoms of 
psychiatric disorders, such as negative thinking and distractibility, are currently a 
challenge to study in rodents due to a lack of established paradigms to tests these 
behaviors. However, there are several well-established animal models of memory 
impairment, another common cognitive symptom of affective disorders (Burt et al., 1995; 
Shelton and Kirwan, 2013). Thus, the cognitive assessments utilized in this thesis are 
learning and recall tests. Specifically, Contextual Fear Conditioning (CFC) and Novel Object 
Recognition (NOR) paradigms were utilized. CFC is an associative learning paradigm in 
which animals are trained to associate a neutral context (conditioned stimulus, CS) with an 
innately aversive stimulus (unconditioned stimulus, US), often foot-shock. During 
subsequent re-exposure to the context alone, learned fear of the CS is measured by 
freezing, the absence of movement except for breathing (Curzon et al., 2009). CFC is 
hippocampus-dependent (Anagnostaras et al., 2001), and different paradigms can be used 
to measure different aspects of learning and memory (Denny et al., 2014). For example, our 
lab has previously shown that mice lacking adult hippocampal neurogenesis are impaired 
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in 1-shock CFC, a brief and therefore challenging learning task, but not 3-shock CFC, a 
paradigm in which the US and CS are presented together multiple times, which is therefore 
less challenging (Denny et al., 2012). NOR is a non-associative memory task in which mice 
are repeatedly presented with two constant objects over several trials. In the last trial, one 
of the constant objects is replaced by a novel object (Antunes and Biala, 2012; Denny et al., 
2012). This test examines the animals’ ability to remember the constant objects over 
several periods of inter-trial delay, as well as their ability to recognize and subsequently 
encode a novel object.  
 
Biological correlates of affective disorders 
In addition to the behavioral dimensions, animal models need to recapitulate the 
physiological changes associated with affective disorders in order to be useful in 
identifying the cellular and molecular mechanisms underlying these conditions. Though the 
underlying biological pathways involved in stress-induced disorders remain largely 
unknown, decreased adult hippocampal neurogenesis and HPA-axis dysregulation are 
associated with psychopathology.  
The dentate gyrus (DG) of the hippocampus is one of two clearly established regions 
of the brain in which new neurons are generated in adulthood (Kaplan and Hinds, 1977; 
Kempermann et al., 1997; Kornack and Rakic, 1999). Newborn adult neurons in the DG, 
which are functionally incorporated into the hippocampal circuit by 4-6 weeks of age, 
display unique properties relative to older mature granule cells (Denny et al., 2012; Ge et 
al., 2007; Lacefield et al., 2012). As a result, this relatively small population of cells is able to 
exert a significant effect on dentate gyrus function (Drew et al., 2013; Lacefield et al., 2012). 
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Levels of adult hippocampal neurogenesis fluctuate throughout the day (Guzman-Marin et 
al., 2007; Smith et al., 2010) as well as over the lifetime of mammals (Kuhn et al., 1996; Seki 
and Arai, 1995), and are modulated by both physiological and psychological factors. Levels 
of adult hippocampal neurogenesis can be quantified by exogenous administration of 5’-
bromo-2’-deoxyuridine (BrdU), which incorporates into the DNA of dividing cells (Cameron 
and McKay, 2001), or by staining for endogenously expressed markers of cell division, such 
as Ki67, or makers of cellular maturation state, such as doublecortin (DCX), which is 
transiently expressed in newborn adult granule cells from approximately 4 days to 2 weeks 
of age (Brown et al., 2003). Importantly, stress has been shown to decreases adult 
hippocampal neurogenesis (Gould and Tanapat, 1999; Mirescu and Gould, 2006; Mirescu et 
al., 2006; Schloesser et al., 2010; Warner-Schmidt and Duman, 2006), and antidepressant 
interventions have been shown to increase neurogenesis (Malberg et al., 2000; Mendez-
David et al., 2014; Schloesser et al., 2010; Warner-Schmidt and Duman, 2006). The 
functional role of adult hippocampal neurogenesis has been studied using x-irradiation and 
transgenic ablation techniques (Denny et al., 2012; Santarelli et al., 2003; Schloesser et al., 
2010), as well as transgenic augmentation strategies (Sahay et al., 2011). Using these tools, 
adult hippocampal neurogenesis has been shown in some models to be necessary both for 
the therapeutic affects of classical antidepressants (David et al., 2007; Santarelli et al., 
2003; Wu and Hen, 2014) and for stress resilience (Lehmann et al., 2013a), and increasing 
neurogenesis alone may be sufficient to induce an antidepressant effect (Hill et al., 2013). 
Rapid-acting antidepressants, however, may work downstream of neurogenesis (Mendez-
David et al., 2014). 
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Additionally, adult hippocampal neurogenesis is known to be involved in contextual 
memory tasks like 1-shock CFC and pattern separation (Denny et al., 2012; Kheirbek et al., 
2012; Sahay et al., 2011; Wu and Hen, 2014), cognitive flexibility (Burghardt et al., 2012), 
and forgetting (Akers et al., 2014). It also regulates the HPA-axis. The HPA-axis, or the 
hypothalamic-pituitary-adrenal axis, is the main stress-responsive system in the body. 
Stress activates the HPA-axis, with the main output being the glucocorticoid steroid 
hormone, cortisol, in humans, and corticosterone, in rodents. Corticosterone acts both 
peripherally and directly on the CNS to, among other things, activate the fight-or-flight 
response (Goldstein, 2010). The hippocampus exerts inhibitory control over the HPA-axis, 
and corticosterone, in turn, regulates hippocampal neurogenesis (Alahmed and Herbert, 
2008; Wong and Herbert, 2006). Dysregulation of the HPA-axis is associated with affective 
disorders (Baumeister et al., 2014; Pariante, 2003) and depressive-like behavior (Gartside 
et al., 2003a; Gartside et al., 2003b; Lehmann et al., 2013a; Leitch et al., 2003; Snyder et al., 
2011), and antidepressant treatments restore HPA-axis responsiveness (Surget et al., 
2011). Furthermore, an intact HPA-axis appears to be necessary for the beneficial effects of 
some antidepressant interventions (Huang and Herbert, 2006; Lehmann et al., 2013a), but 
further studies are needed to dissect the contribution of glucocorticoids to the 
antidepressant response. 
Because HPA-axis dysregulation and changes in hippocampal neurogenesis are both 
implicated in the pathophysiology of depression and the mechanism of action of classical 
antidepressants, they are logical biological correlates to examine when characterizing 




In this thesis, we asked several questions relating to affective disorders and antidepressant 
interventions using the chronic social defeat stress model of stress-induced 
psychopathology. Overall, we determined if SD is a valid model for the study of affective 
disorders, identified a cellular correlate of stress-induced cognitive impairment, and 
explored the rapid-acting antidepressant and resilience-enhancing properties of ketamine 
in the SD model. Specifically, we tested the following hypotheses: 
1. The chronic social defeat stress mouse model recapitulates several of the dimensions 
of psychiatric disorder symptoms, including cognitive deficits, making it a valid model 
to study stress-induced psychopathology. There are cellular correlates for the 
behavioral deficits induced by chronic stress. 
2. Ketamine works as a rapid-acting antidepressant in the social defeat model. 




















Chronic social defeat stress (SD) is a novel, etiologically relevant animal model that allows 
for the study of depressive-like behavior in mice. This model is unique in that it 
incorporates the social component of affective disorders. Here, an experimental mouse is 
co-housed with a dominant aggressor mouse and thus, subjected to chronic SD. As different 
types of stressors cause different physiological and behavioral changes (Blanchard et al., 
2001), and as the predominance of stress-induced depression is caused by psychosocial 
stress (Brown and Prudo, 1981), chronic SD stress offers an additional layer of construct 
validity when compared to other animal models of affective disorders.  
As psychiatric disorders are diagnosed by symptomology, a valid animal model 
needs to recapitulate the major symptom clusters present in stress-induced 
psychopathology. In addition to depressive and anxious symptoms, many psychiatric 
disorders, like major depressive disorder (MDD) and post-traumatic stress disorder 
(PTSD), are characterized by cognitive impairments (Behnken et al., 2010; Nagane et al., 
2014). In this study, in addition to the more typically studied alterations in mood, we also 
characterized stress-induced cognitive deficits on both a behavioral and cellular level.  
The transgenic mice utilized in this study are on a 129S6/SvEvTac, C57Bl/6J, and 
CBA mixed background, an experimental strain that had not previously been tested in SD. 
We first established that SD reliably and robustly induced depressive-like and anxious 
behavior in this strain. We also found that SD in this strain decreased adult hippocampal 
neurogenesis, a cellular correlate of depressive-like behavior, but seemingly not to the 
extent previously observed in C57Bl/6J mice (Lehmann et al., 2013a; Schloesser et al., 
2010). Having established the SD model in this strain, in order to test whether the SD 
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paradigm could also be used to investigate stress-induced cognitive deficits, we then tested 
mice in two different cognitive assays: novel object recognition (NOR) and contextual fear 
conditioning (CFC). SD mice showed increased novel object exploration, suggesting a deficit 
in encoding the novel object, and were also impaired in contextual fear learning.  
Having identified a robust chronic stress-induced impairment in CFC, we strove to 
identify if there was a cellular correlate of this deficit. Additionally, we were interested if 
alterations in activation patterns in defeated mice implicated impairment in a specific stage 
of contextual fear memory formation, either encoding or expression. In order to ask these 
questions, we utilized an ArcCreERT2 bacterial artificial chromosome (BAC) transgenic 
mouse that allows for the visualization of two different populations of cells activated at 
distinct time-points. Using this transgenic mouse, we were able to indelibly label the 
population of cells activated during encoding in contextual fear conditioning and 
subsequently compare this population to the population of cells activated during 
expression of a fear memory.  
We chose to investigate reactivation patterns in the hippocampus, an area of the 
brain known to be essential for episodic and contextual memory formation, storage, and 
retrieval (Bakker et al., 2008; Leutgeb et al., 2007; Marr, 1971; McHugh et al., 2007; O'Reilly 
and McClelland, 1994; Treves and Rolls, 1992). We focused specifically on activation in the 
dentate gyrus (DG) subregion of the hippocampus (HPC), as 1) both of the cognitive tasks 
we explored are known to be DG-dependent (Denny et al., 2012), and 2) social defeat stress 
alters the cellular architecture of the dentate by decreasing adult neurogenesis. We 
additionally chose to look at reactivation patterns in the CA3 subregion, as it is a direct 
downstream target of the dentate and has been posited to be involved in pattern 
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completion (Treves and Rolls, 1992). We hypothesized that the cells reactivated in these 
regions of the hippocampus during expression of a memory are a component of the 
memory trace, and that mice with impaired recall would show less cellular reactivation. We 
found that levels of reactivation in CA3 are decreased in mice with impaired fear memory 




Materials and Methods 
Generation of BAC transgene and transgenic animals 
A BAC clone (RP23-429N15) that contained the entire mouse Arc/Arg3.1 gene was 
obtained from the BACPAC Resources Center (BPRC, http://bacpac.chori.org). The 
pBADTcTypeG plasmid (a gift from Dr. Manabu Nakayama, Kazusa Institute, Japan) was 
transferred into DH10B cells contained the BAC clone, enabling Red/ET homologous 
recombination system. A DNA fragment containing a Rpsl-Zeo cassette (a gift from Dr. 
Hisashi Mori, Toyama University, Japan), with 50 bp homology arms, was electroporated 
into cells and the Rpsl-Zeo cassette was then inserted into the translation initiation site of 
the Arc/Arg3.1 gene, resulting in Zeocin resistant and streptomycin sensitive cells. A DNA 
fragment containing the CreERT2-SV40 polyA cassette (a gift from Pierre Chambon) with 
300 bp homology arms was electroporated and streptomycin resistant clones were 
selected. The Rpsl-Zeo cassette was replaced with CreERT2-SV40 polyA cassette, resulting 
in CreERT2 being expressed under the control of the Arc promoter.    
 To remove LoxP sites that were present in the BAC backbone, which, if present, could 
result in inter-chromosomal recombination between LoxP sites in the reporter allele and 
BAC transgene upon activation of CreERT2, an additional modification of the Arc BAC was 
made. The loxP site in the pBACe3.6 was replaced with a Zeo cassette (p23loxZeo) (a gift 
from Kousuke Yusa, Osaka University, Japan) by recombination. After a targeting procedure 
was completed, removal of the LoxP site was confirmed by PCR.  
For generation of transgenic animals, ArcCreERT2 BAC DNA was linearized by PI-SceI 
enzyme digestion (New England Biolabs Inc., Ipswich, MA, USA) and injected into fertilized 
eggs from CBA / C57Bl/6J mice. Two founders (1 female and 1 male) resulted from 
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injection and both lines have been maintained. Mice derived from the M line are described 
within this thesis. 
Transgenic (Tg) mice generated using ArcCreERT2 BAC DNA are hereafter referred 
to as ArcCreERT2 mice. Gt(ROSA)26Sortm1(EYFP)Cos/J mice [R26R-STOP-floxed-enhanced 
yellow fluorescent protein (EYFP) mice] (Srinivas et al., 2001) were a gift of Dr. Stephen 
Rayport. Mice were maintained on a mixed background consisting of mostly 129SvEv/Tac, 
C57Bl/6J, and CBA.     
CD-1 mice were purchased from Charles River Laboratories (Wilmington, MA) at 8-
10 weeks of age and housed individually. 
 
Genotyping 
Founders and subsequent offspring were genotyped using the following primer sets. Cre: 
5’-GCC TGC ATT ACC GGT CGA TGC AAC G-3’; 5’-AAA TCC ATC GCT CGA CCA GTT TAG TTA 
CCC-3’. R26R: 5’-GGA GCG GGA GAA ATG GAT ATG-3’; 5’-AAA GTC GCT CTG AGT TGT TAT-
3’; 5’-AAG ACC GCG AAG AGT TTG TC-3’. The Cre and R26R genotyping were performed 
separately. The R26R genotyping was performed according to The Jackson Laboratory 
genotyping protocol (The Jackson Laboratory, Bar Harbor, ME). 
 
Social Defeat (SD) 
Adult aggressor CD-1 male mice were single-housed in a Macrolon® polycarbonate resin 
cages (15.25 in. x 7.8 in x 9.5 in) (Animal Care Systems, Inc., Centennial, CO). Male 
ArcCreERT2(+) x R26R-STOP-floxed-EYFP(+/-) mice (approximately 8.5 weeks of age) were 
subsequently placed into the resident CD-1 mouse’s cage. Three antagonistic encounters 
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were allowed between the CD-1 mouse and the intruder. Following the encounters, a 
polished stainless steel cage divider (Animal Care Systems, Inc., Centennial, CO, P/N 
C79171), which allowed for olfactory and auditory communication, but not visual or tactile 
contact to occur, was placed down the middle to separate the two mice. The partition was 
removed daily for 2 weeks and 3 antagonistic encounters were allowed between the mice 
each day. Control (Ctrl) mice were group housed in the same cages. 
 
Open Field (OF) 
Exploration in response to a novel open field (OF) was measured as previously described 
(Richardson-Jones et al., 2010). OF was run both in light conditions (high anxiety) and dark 
conditions (low anxiety). The % center distance was calculated as a ratio (center distance 
(C dist) / (center + periphery distance (C + P dist)). 
 
Tail Suspension Test (TST) 
Mice were suspended by the tail using tape to secure them to a horizontal bar, as 
previously described (Richardson-Jones et al., 2010). Briefly, animals were suspended for 5 
min and immobility during this period was assessed using an automated Viewpoint 
Videotrack software package. 
 
Social Interaction (SI) 
Social interaction was performed as previously described (Lehmann et al., 2013a; 
Schloesser et al., 2010) with the exception that mice were allowed to explore for 30 min 
and the first 10 min were later analyzed. Sessions were videotaped and analyzed using 
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behavioral tracking software (TopScan, CleverSys, Reston, VA, USA). This software reliably 
scores the frequency and duration of interactions with either object or mouse through 
identification of the shape of a mouse, to include nose, body, and tail. Interaction ratios 
were calculated using an interaction quotient (interaction with CD-1 / (interaction with 
CD-1 + interaction with empty enclosure)). 
 
Elevated Plus Maze (EPM) 
The elevated plus maze was performed as previously described (Saxe et al., 2006). 
 
Contextual Fear Conditioning (CFC) 
Apparati: Context A was a chamber obtained from Coulbourn (Coulbourn Instruments, 
Whitehall, PA) with internal dimensions of 7 in x 7 in x 12 in. The chamber had clear plastic 
front and back walls, stainless steel walls on each side, and stainless steel bars on the floor. 
A house light was mounted directly above the chamber. Each chamber was located inside a 
larger, insulated, plastic cabinet that provided protection from outside light and noise. Each 
cabinet contained a ventilation fan that was operated during the sessions. A paper towel 
dabbed with lemon solution was placed under the stainless steel bars. The scent was 
refreshed every fourth run. Mice were held outside the experimental room in their home 
cages prior to testing and transported to the conditioning apparatus in standard mouse 
cages. Chambers were cleaned with 70% EtOH between each run. 
Protocol: The 1-shock CFC procedure was based on those of Wiltgen et al. (2006), 
Drew et al. (2010), and Denny et al. (2012). Mice were placed into the conditioning 
chamber, received 1 shock at 180 s (2 s, 0.75 mA), and were removed 15 s following the 
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shock. CFC context re-exposure was conducted with the conditioning chambers configured 
exactly as during the CFC training (see description of context A). The length of context re-
exposure was 180 s, the same length of CFC training. Mice were re-exposed to the training 
context 5 days after CFC training. For cellular labeling experiments, the CFC training and 
memory expression took place on day 2 and day 7, respectively, as described below. 
The datasets from CFC training and encoding were subjected to Training x Group 
repeated measures ANOVA. Freezing was scoring for the 180 s before the onset of the first 
shock and for the 15 s following the last shock. The datasets from context exposure were 
subjected to a 2 (Ctrl versus SD) x 3-6 (Minute) repeated measures ANOVA with Minute as 
the repeated measure.  
 
Novel Object Recognition (NOR) 
NOR was performed as previously described (Denny et al., 2012). Briefly, we used a 
modified version of the NOR task described by Ennaceur and Delacour (1988). The testing 
room was lit with two 60-W light bulbs and behavior sessions were recorded with a video 
camera affixed to a tripod above the testing arena. The testing arena was a white, plastic 
transport box (55 x 40 x 15 cm3) and was divided into two equal halves so that two 
sessions could occur simultaneously. The divider was made of the same white plastic as the 
transport box and measured 15 cm in height. Mice could not contact or see one another 
during the exposures. The transport box was filled with wooden bedding. The light 
intensity was equal in all parts of the arena (~ 20 lx). When the arena was superimposed 




Recombination in ArcCreERT2 x R26R-STOP-floxed-EYFP transgenic mice was induced 
using tamoxifen (TAM) (Sigma, St. Louis, MO, T5648). TAM was dissolved by sonication in 
10% EtOH / 90% corn oil at a concentration of 10 mg/ml. One injection of 200 μl (2 mg) 
was injected intraperitoneally (i.p.) into adult mice. 
A cohort of Ctrl and SD mice were also injected with 5’-bromo-2’-deoxyuridine 
(BrdU) (Roche, Indianapolis, IN) (150 mg/kg) twice a day i.p. for 5 days (300 mg/kg per 
day in 0.9% NaCl) one week prior to the start of SD. 
 
Standard Housing and Dark Housing 
Mice were housed four to five per cage in a 12-h (06:00-18:00) light-dark colony room at 
22°C. Food and water were provided ad libitum. Behavioral testing was performed during 
the light phase. For cellular labeling experiments, cages were changed and mice were 
placed into a separate housing room the night before the TAM injection (day 1). The next 
day, mice were injected with TAM and administered CFC 5 h later (day 2). Following the 
behavioral task, mice were placed into the dark for that night and the following three days 
(days 3-5). Mice were taken out of the dark, cages were changed, and they were returned to 
the normal colony room. 
Mice were returned to the testing room on day 7 for assessment of fear memory 
expression. It was imperative that their cages were not changed the day of or the day 
before the memory expression test. All precautions to prevent disturbances to the 
ArcCreERT2 mice were taken. The procedures described herein were conducted in 
accordance with National Institutes of Health regulations and approved by the Institutional 
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Mice were deeply anesthetized and brains were processed as previously described (Denny 
et al., 2012). For Arc and YFP double immunohistochemistry, or c-fos and YFP double 
immunohistochemistry, floating sections were used. Sections were first rinsed three times 
in 1X PBS and then blocked in 1X PBS with 0.5% Triton and 10% normal donkey serum 
(NDS) for 2 h at RT. Incubation with primary antibodies was performed at 4°C overnight 
(rabbit anti-Arc, 1:1000, SySy, Göttingen, Germany, 156 003; chicken anti-GFP 1:500, 
Abcam, Cambridge, MA, ab13970, rabbit anti-c-fos, 1:5000, Calbiochem, Darmstadt, 
Germany) in 1X PBS with 0.5% Triton X-100. Sections were then washed three times in 1X 
PBS and incubated with secondary antibodies (donkey anti-rabbit Cy3; biotinylated donkey 
anti-chicken; 1:500, Jackson ImmunoResearch, West Grove, PA) for 2 h at RT. Sections were 
then washed three times in 1X PBS and incubated with a tertiary antibody (avidin-Cy2, 
1:250, Jackson ImmunoResearch, WestGrove, PA) and Hoechst (1:1000) for 1 h at RT. 
Sections were washed three times in 1X PBS, mounted on slides, and cover slipped with 
ProLong Gold (Invitrogen, Carlsbad, CA). 




For individual counts, an investigator blind to treatment used a Zeiss Axioplan-2 upright 
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microscope (Oberkochen, Germany) to count EYFP+, Arc+, Brdu+, and c-fos+ 
immunoreactive cells bilaterally in the granule cell layer (GCL) of the DG and in CA3 
throughout the entire rostro-caudal axis of the hippocampus (HPC) (Burghardt et al., 2012; 
Meshi et al., 2006; Santarelli et al., 2003). Every sixth section throughout the entire extent 
of the HPC was included in the analysis. Cells were counted bilaterally using the 20X 




For co-labeled cells, fluorescent confocal micrographs were captured with an Olympus 
Fluoview™ FV1000 confocal microscope with the aid of Olympus Fluoview 1000v1.5 
software. Identification of co-expressing cells in the DG (EYFP+/Arc+, EYFP+/c-fos+) 
entailed scanning approximately 24 sections throughout the HPC of each mouse at 20X. 
Phenotyping of co-expressing cells in CA3 (EYFP+/c-fos+) entailed scanning approximately 
10 sections throughout CA3 of each mouse at 20X. All individual panels were acquired at 
thickness of 1.41 mm. Each channel was acquired in “Sequential Mode, Frame” so as to only 
excite that particular fluorophore, avoid bleed through, and prevent emission spectral 
overlap. All scans were acquired using the “Integration Type, Line Kalman,” in order to 
significantly increase the signal to noise ratio. Furthermore, we utilized the carbocyanine 
(Cy series) dyes (e.g. Cy2 and Cy3), as these designed organic molecules have a narrow 
emission spectra when compared with older probes. 
Split-panel and z-stack analysis was performed using Olympus Fluoview Ver 2.0c 
Viewer to determine ratios of EYFP+/Arc+ or EYFP+/c-fos+ double-labeled cells. To 
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identify co-labeled cells, we looked at images one channel at a time (e.g. Arc labeled with 
Cy3). Cells that had signal above background were marked as positive and counted. 
Separate Cy2 and Cy3 filtered images were digitally combined to produce composite 
images. Throughout the experiment, the investigator was blind to the treatment status. 
Representative images were edited using Adobe Photoshop CS4 and all images were 
treated identically. 
To obtain % reactivation cells, we counted the total number of Arc+ or c-fos+ cells in 
a confocal image. The number of Arc+ or c-fos+ cells that were co-labeled with EYFP was 
then counted. The ratio is expressed as ((EYFP+/Arc+) / Arc+) x 100%. 
 
Statistical Analysis 
In general, the effect of treatment or context was analyzed using an ANOVA, using repeated 
measures where appropriate. Significant ANOVAs were followed up with Fisher’s PLSD 
tests where appropriate. All main effects and interactions are noted in the text.  
For analyses on EYFP+, Arc+, c-fos+, EYFP+/Arc+, or EYFP+/c-fos+ counts, 
statistical significance was assessed by using an unpaired two-tailed Student’s t-test. P 
values are noted throughout the text. 
All data were analyzed using StatView 5.0 software (SAS Institute, Cary, NC). Alpha 
was set to 0.05 for all analyses. Data are expressed as means + SEM. * p < 0.05, ** p < 0.01, 
*** p < 0.001.
 
Results and Figures 
We hypothesized that chronic social defeat (SD) stress would induce depressive
anxious behavior in our transgenic 
Additionally, we hypothesized that SD would induce cognitive deficits in these mice. To test 
these hypotheses, ArcCreERT2 x R26R
weeks or control (Ctrl) housed 4
paradigms were administered following SD.
and SD mice were administered a 1
training context 5 days later and sacrificed 1 h later. 
Figure 2.1. Experimental timeline.
as Ctrl mice prior to behavioral testing. Tests were administered in order of increasing 
inherent stressfulness. Mice were tested in novel object recognition (NOR) the day after the 
completion of SD. They were subsequently tested in open field (OF) in both light and dark 
conditions (2 days post-SD), elevated plus maze (EPM) (3 days post
(SI) (4 days post-SD), novelty suppressed feeding (NSF) (5 days post
(TST) (6 days post-SD), trained in contextual fear conditioning (CFC) on the 11




Social defeat did not alter average body weight in ArcCreER
Average body weight was comparable in Ctrl and SD groups prior to SD (
after 2 weeks of SD (Figure 2.2B
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ArcCreERT2 x R26R-STOP-floxed-EYFP mice. 
-STOP-floxed-EYFP mice were subjected to SD 
-5 mice per cage (Figure 2.1). A number of behavioral 
 Finally, 10 days after the cessation of SD, Ctrl 
-shock CFC paradigm. Mice were then re
 
 Mice underwent two weeks of SD or were group housed 
-SD), social interaction 
-SD), tail suspension 
th day post-SD, and sacrificed 1 hour after CFC 
T2 x R26R-STOP-floxed
Figure 2.2A
) (p’s > 0.05).  
-like and 
for 2 






Figure 2.2. SD did not affect average body weight. 
start of and (B) following social defeat (SD) (p’s > 0.05). (n = 4
represent + SEM. 
 
Social defeat results in a depressive
mice 
Decreased willingness to interact with the dominant aggressor with which they are co
housed is considered the most sensitive measure of depressive
mice (Lehmann et al., 2013a; Schloesser et al., 2010)
is often reported as compared to interaction with a control object. SD mice approached the 
social object (CD-1) significantly less than Ctrl mice (p = 0.0
approached the non-social control object significantly more times than Ctrl mice (p < 0.01) 
(Figure 2.3A). SD mice had a significantly lower interaction quotient, the amount of time 
spent interacting with the CD-1 as a fraction of to




Body weight did not differ 
-13 mice / group). Error bars 
-like phenotype in ArcCreERT2 x R26R-STOP
-like behavior induced in SD 
. Willingness to interact with the CD
4) (Figure 2.3A
tal time spent interacting with either the 
Figure 2.3B).  




). SD mice 
 
Figure 2.3. SD decreases social interaction, a measure of depressive
SI paradigm, SD mice exhibited significantly 
0.04) and significantly more approaches to the empty enclosure (p < 0.01). (
interaction quotient was significantly less in SD mice (p = 0.02). (n = 4
< 0.05. ** p < 0.01. Error bars re
 
In addition to social interaction, we tested mice in tail suspension (TST), another test of 
depressive-like behavior. In TST, SD mice displayed significantly more immobility, a 
measure of depressive-like behavior, when compared to Ctrl mice




less approaches to the CD-1 aggressor (p = 
-13 mice / group). * p 
present + SEM. 
 [F(1,18) = 8.614, p < 
 
(A) In the 
B) The 
 
Figure 2.4. SD increases depressive
increased immobility when compared to Ctrl mice 
mice / group). * p < 0.05. ** p < 0.01.
 
Taken together, decreased interaction with the CD
immobility in TST indicate that SD robustly induced a depressive
ArcCreERT2 mice. 
 
Social defeat stress increases anxiety 
In order to test if SD also increased anxiety levels in the ArcCreER
mice in two anxiety tests: elevated plus maze (EPM) and open field (OF).  SD mice spent 
significantly less time in the open arms of the EPM when compared to Ctrl mice, which is 







-like behavior in TST. In TST, SD mice displayed 
[F(1,18) = 8.614, p < 0.01]. (n = 4
 Error bars represent + SEM. 
-1 aggressor in SI and increased 
-like phenotype in the 
in ArcCreERT2 x R26R-STOP-floxed-EYFP mice
T2 mice, we tested the 




Figure 2.5. SD increases anxiety in EPM. 
arms when compared to Ctrl mice 
represent + SEM. 
 
 
SD did not, however, impact OF exploration. We f
dark conditions to confirm no baseline differences in locomotion. There was no difference 
in basic movements (Figure 2.6A
between SD and Ctrl mice in the OF in dark con
conditions, which are more anxiogenic, distance traveled proximal to the periphery (P) is 
considered a measure of anxiety, as compared to distance traveled in the more exposed 
center of the arena (center, C). 
levels of locomotion (p > 0.05) (
distance (p > 0.05) (Figure 2.6D





In the EPM, SD mice spend less time in the open 
(p = 0.02). (n = 4-13 mice / group). * p < 0.05. Error bars 
irst tested mice in less anxiogenic 
) or % distance traveled in the center (Figure 2.6B
ditions (p’s > 0.05). In bright light 
In light conditions, Ctrl and SD mice displayed comparable 
Figure 2.6C). They also had similar levels of % center 
), suggesting there was no difference in anxiety between 
) 
 
      
Figure 2.6. SD did not effect behavior in the OF. 
between Ctrl and SD mice. (n = 4
 
Social defeat stress induces cognitive deficits in novel object
conditioning 
Though cognitive impairment is a major aspect of psychiatric disorders, it is often 
overlooked in animal models. In order to test if SD was sufficient to induce cognitive 
deficits, we tested mice in two differe
34 
    
 
In the OF, no differences were detected 
-13 mice / group). Error bars represent + SEM.
 recognition and contextual fear 
nt memory tasks: novel objet recognition (NOR) and 
 
 
contextual fear conditioning (CFC).
 In NOR, mice are exposed to two constant objects over four habituation exposures 
before one of the objects is replaced by a novel object in the fifth exposure. General 
(Figure 2.7A) and object investigation (
which mice were re-exposed to the same two initial objects, as expected. There was no 
difference between groups in either activity or exploration for the first fo
> 0.05) (Figure 2.7A-B). This suggests that SD mice are not impaired in ability to 
remember the constant objects over the 3
exposures. In the fifth exposure, SD mice spent significantly more time inv
novel object than Ctrl mice (p = 0.02) (
an impaired ability to encode the novel object 
 
Figure 2.7. Chronic stress impairs novel object encoding.
activity and investigation declined across exposures 1
investigated the novel object more than Ctrl mice (p = 0.02). (n = 4




Figure 2.7B) decreased over exposures 1
ur exposures (p’s 
-minute inter-exposure interval between 
estigating the 
Figure 2.7C), which is hypothesized to result from
(Denny et al., 2012). 
 (A) In NOR paradigm, general 
-4 for Ctrl and SD mice. (






B) SD mice 
 
In 1-shock CFC, mice were administered a single shock (unconditioned stimulus) in context 
A (conditioned stimulus), and then re
Freezing was quantified as a measure of fear memory expression. Fo
SD mice displayed significantly less freezing than Ctrl mice when re
context [F(1,18) = 11.717, p = 0.0030] 
SD impairs contextual fear learning and memory.
 
Figure 2.8. SD mice are impaired in 1
reduced in SD mice. [F(1,17) = 4.593, p < 0.05]. (n = 4
bars represent + SEM. 
 
Social defeat stress decreases adult hippocampal
Adult hippocampal neurogenesis is one of the few cellular processes that corresponds with 
affective behavioral state (Lehmann et al., 2013a; Santarelli et al., 2003; Schloesser et al., 
2010; Surget et al., 2011). We have previously shown that SD decreases survi
proliferation, of newborn neurons in the ventral portion of the dentate gyrus (DG) of 
C57Bl/6J mice (Lehmann et al., 2013a; Schloesser et al., 2010)
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-exposed to context A to test associative fear learning. 
llowing CFC training, 
-exposed to the training 
(Figure 2.8). This demonstrates that two weeks of 
 
 
-shock CFC. Context-elicited freezing was significantly 
-13 mice / group). * p < 0.05. Error 
 neurogenesis 
. To determine if SD 
val, but not 
 
decreases neurogenesis in ArcCreER
ventral DG. We found that SD significantly decreased the number of BrdU+ cells in the most 
ventral section of the DG (p < 0.01) 
hippocampal neurogenesis in ArcCreER
 
Figure 2.9. SD decreases adult 
significantly less in SD mice in the most ventral DG section (p < 0.01). (n = 4
group). ** p < 0.01. Error bars represent + SEM.
 
 
Decreased reactivation in CA3 but not in the DG correlates with stress
impairment 
Having discovered a robust deficit in a HPC
as cellular changes in the DG induced by SD, we hypothesized that a
this memory impairment might exist in the DG or an associated hippocampal structure. 
Within the DG and its associated downstream target, CA3, immediate early genes (IEGs) are 
typically expressed in a sparse pattern 
recombination in the ArcCreER
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encoding of a memory versus cells activated during the expression of that memory. 
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Figure 2.10. Experimental paradigm to separately label cell populations involved in 
encoding and retrieval. (A) Mice
following the end of SD, mice were
context A 5 days later, and sacrificed 1 h later. (
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           Following sacrifice and staining, we quantified the number of cells activated during 
encoding (EYFP+) and retrieval (Arc+ or c-fos+) in the DG and CA3, a region of the HPC that 
receives direct downstream output from the DG. In the DG, neither the number of EYFP+ 
cells (p = 0.90) (Figure 2.11A) nor the number of Arc+ cells (p = 0.10) (Figure 4.11B) 
differed between Ctrl and SD mice. The percent of co-labeled EYFP+/Arc+ cells was also 
similar between the groups (p = 0.63) (Figures 4.11C-D), suggesting the DG is capable of 
encoding and retrieving contextual information in a similar manner following stressful 





















Figure 2.11. SD did not alter cellular activation patterns in the DG. 
number of EYFP+ (p = 0.69) and (
mice. (C) Ctrl and SD mice had a comparable percent of co
= 0.63). (D) Representative image of the immunohistochemistry in the DG. Scale bar 
represents 100 microns. n = 4-10 mice per group). Error bars represent + SEM.
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reactivation in CA3, as measured by 
impairment in 1-shock CFC exhibited by SD mice. These data suggest that reactivation in 
CA3, rather than in the DG, is related to the strength of the memory trace. 
Figure 2.12. The stress-induced 1
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In this study, we endeavored to characterize the chronic SD stress animal model of 
depression along multiple symptom dimensions: depressive-like behavior, anxiety, and 
cognitive impairment. As psychiatric disorders are diagnosed by symptomology, it is 
essential that animal models of the disorders recapitulate symptoms across several 
behavioral axes. In our mixed background mouse strain, we found that SD robustly and 
reliably induced depressive-like behavior, as seen by decreased social interaction and 
increased immobility in TST. SD also increased anxiety in the ArcCreERT2 mice, as 
demonstrated by decreased time in the open arms in EPM. Having established that SD was 
effective in the ArcCreERT2 mice, and resulted in less resilience than is often seen in other 
strains (Krishnan et al., 2007), we then examined SD ArcCreERT2 mice in 2 memory tasks: 
NOR and 1-shock CFC. Though cognition is not as frequently studied as affective behaviors 
in psychiatric models, it is an important component of mood disorders. SD induced 
cognitive deficits in both NOR and 1-shock CFC. In addition to altering affective and 
cognitive behavior, SD also decreased adult hippocampal neurogenesis in the ventral 
portion of the DG. 
 Having identified a robust cognitive deficit in contextual fear memory, as well as 
cellular correlate of stress-induced changes in affective state (decreased neurogenesis), we 
hypothesized that the 1-shock impairment corresponds with a deficit in cellular memory 
trace formation. The ArcCreERT2 mouse is a novel transgenic tool that allows for labeling of 
two separate populations of cells involved in learning and memory. Using the ArcCreERT2 
mice, we have previously shown that cells reactivated in the DG and CA3 are a component 
of the memory trace for the fearful context A (Denny et al., 2014). Using the ArcCreERT2 
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mice, we were able to assess the impact of SD on the extent of neuronal reactivation in the 
DG and in CA3 during retrieval of a contextual fear memory.  
 In both the DG and the CA3, we found that the total number of cells activated during 
CFC encoding (EYFP+ cells) did not differ between Ctrl and SD mice. Though at first the 
absence of a difference in the DG seems somewhat surprising, seeing as SD decreases adult 
hippocampal neurogenesis, recent studies suggest that young adult-born hippocampal 
neurons are not preferentially recruited during encoding (Stone et al., 2011). Since young 
neurons represent only 5-10% of the total granule cell population, it is therefore not 
surprising that in our studies the total number of EYFP+ cells in the DG is not significantly 
different between Ctrl and SD mice, despite the decreased number of young neurons in the 
SD mice. During CFC memory retrieval, the number of Arc+ cells in the DG and the number 
of c-fos+ cells in CA3 were also similar between Ctrl and SD mice. Somewhat more 
surprisingly, the percentage of reactivated cells does not change in the DG while it does in 
CA3 in SD mice when compared to Ctrl mice. This decreased reactivation in CA3 
corresponds with decreased expression of the 1-shock CFC memory. These results indicate 
that levels of reactivation in CA3, rather than in the DG, are related to the strength of the 
memory. Together, these data support the hypothesis that the number of cells reactivated 
during memory retrieval is related to the strength of the memory and are consistent with 
the notion that these cells contribute to the memory trace.  
Interestingly, levels of activity during encoding are higher in the DG than in 
CA3, which may reflect a preferential role of the DG in encoding (Kheirbek et al., 2013; Lee 
and Kesner, 2004). Additionally, levels of activation are higher in CA3 during retrieval than 
encoding (Denny et al., 2014). In this manner, chronic SD-induced deficits in contextual fear 
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memory may not reflect a deficit in encoding, but instead a deficit in memory expression or 
retrieval.  
Taken together, these data indicate that cognitive deficits seen in psychiatric 
disorders can be recapitulated in models of stress-induced psychopathology. The 
impairment in cellular reactivation in CA3 in contextual fear memory formation gives us 
novel insight into regions to explore in patients with MDD, PTSD, and other stress-
associated affective disorders. As SD decreases adult hippocampal neurogenesis, and it has 
been previously shown that ablating adult hippocampal neurogenesis is sufficient to induce 
impairment in CFC, it will be interesting to see if antidepressant interventions that increase 
neurogenesis also ameliorate memory deficits. 
  In conclusion, though cognitive dysfunction is known to be a core symptom of 
affective disorders like MDD, it is woefully understudied and poorly treated (Austin et al., 
2001; Hammi et al., 2014). Moving forward, it is essential that animal models exploring 
both the pathophysiology underlying mood disorders, as well as antidepressant 
interventions to treat them, take into consideration changes in cognition. By studying 
cognitive impairment, in addition to the more traditional focus on depressive and anxious 
behavior, we have the potential to significantly advance our understanding of the cellular 





















A single injection of ketamine following chronic social defeat stress has a modest rapid-onset 





Major Depressive Disorder (MDD) is a debilitating disease characterized by recurring 
episodes of low mood, anhedonia, and lack of motivation. An estimated 350 million people 
worldwide suffer from depression, with approximately 1 million deaths per year resulting 
from associated suicide (WHO, 2012). Despite the overwhelming prevalence and burden of 
this disease, still much remains unknown about the etiology and pathophysiology of 
depression. As a result, treatment options are imperfect at best: the most commonly used 
pharmacological interventions have undesirable side effect profiles and a delayed onset of 
therapeutic efficacy of approximately four to six weeks (Quitkin et al., 1996). In addition to 
this delay in efficacy being generally undesirable for patients suffering from depression, it 
can be life threatening in cases of suicidality. Furthermore, traditional antidepressants are 
ineffective in a large subset of patients with treatment-resistant depression (Penn and 
Tracy, 2012). 
Ketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, 
has recently been found to have rapid-acting antidepressant effects in humans (Mathew et 
al., 2008). With therapeutic response observed as rapidly as 2 hours following a single dose 
(Zarate et al., 2006), ketamine could potentially fill the 4-6 week efficacy gap that has 
plagued patients and practitioners since the discovery of tricyclic antidepressants in the 
1950s (Lieberman, 2003). Additionally, a single subanesthetic dose of ketamine can have 
long-lasting effects (Zarate et al., 2006)—persisting for days to weeks—and has also been 
found to induce remission in many previously treatment-resistant patients (Murrough et 
al., 2013b). However, ketamine has many undesirable side effects, including dissociative 
hallucinations, and a great potential for abuse (Jolly and McLean, 2012). Ketamine also 
 47 
modulates a myriad of different biological systems (Jolly and McLean, 2012). For these 
reasons, many practitioners view ketamine as a prototype for rapid-acting antidepressants, 
and rather than prescribing it, instead await the second generation of glutamatergic 
antidepressants (Caddy et al., 2014). By identifying the mechanism by which ketamine 
exerts its antidepressant action, we can begin to develop more targeted (i.e., cleaner) and 
safer rapid-acting drugs.  
In order to examine the mechanism of action underlying ketamine’s rapid-acting 
antidepressant effect, we need to employ animal models. Though genetic, stress-induced, 
and baseline strain mouse models of psychiatric disorders are available for use, the 
majority of ketamine mouse research has been done in strains that do not typically show 
baseline responses to antidepressant treatment (e.g., CD-1 and C57Bl/6J mice) (Bechtholt-
Gompf et al., 2011; da Silva et al., 2010; Kos et al., 2006; Lindholm et al., 2012; Maeng et al., 
2008; Owolabi et al., 2014; Popik et al., 2008). More problematic, however, is that the 
‘antidepressant’ effect of ketamine has most commonly been confirmed using tests that are 
also predictive of antidepressant efficacy (Table 3.1).  
As is well established from the classical antidepressant literature, certain tests, such 
as the Forced Swim Test (FST), are predictive of antidepressant effects (Porsolt et al., 
1978a). This means that even drugs that do not obtain antidepressant efficacy unless 
administered chronically will still increase mobility when administered acutely in FST. Just 
as we would not attempt to study the molecular mechanisms underlying the classical 
antidepressants without waiting the several weeks required for the onset of therapeutic 
efficacy, there is a concern that studies attempting to elucidate ketamine’s antidepressant 
mechanism of action using only acute FST may not have actually established 
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antidepressant efficacy. Instead, these reports conflate the predictive validity of FST with 
face validity. Maeng and colleagues were acutely aware of the confounds of only showing 
an effect of ketamine in tests that respond to acute classical antidepressant administration 
(e.g., FST), and attempted to address this in their work (Maeng et al., 2008). However, even 
in their studies, they used non-stressed C57Bl6 mice (Bechtholt-Gompf et al., 2011). When 
one filters the mouse literature for behavioral tests that are only responsive after 
antidepressant efficacy is obtained (i.e., non-pharmacologically predictive), essentially only 
established depression models (social defeat, chronic mild stress, learned helplessness) 
show an effect of ketamine (Figure 3.1). In this manner, the antidepressant effect of 
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Additionally, the anxiolytic effects of ketamine have not been extensively studied. 
Some groups have reported that ketamine is actually anxiogenic is certain types of anxiety 
tests (Babar et al., 2001; da Silva et al., 2010). Whether ketamine is effective in ameliorating 
the cognitive impairments associated with affective disorders also has yet to be addressed. 
In order to more fully characterize the antidepressant effects of ketamine in mice, 
we used a chronic social defeat (SD) stress paradigm in a 129S6/SvEvTac (129) mouse 
strain. We identified 30 mg/kg ketamine as the lowest dose that acutely increased mobility 
in FST in 129 mice and this dose was then used in subsequent stress experiments. In order 
to establish this working dose of ketamine, we conducted several dose titration studies and 
compared acute responses in FST across four different strains.  
To assess the antidepressant effects of ketamine, 129 mice were subjected to 2 
weeks of SD. Following SD, experimental mice were administered a single subanesthetic 
injection of either saline (Sal) or ketamine (K) and underwent behavioral testing to identify 
if ketamine treatment was sufficient to ameliorate depressive-like, anxious, and cognitive 
symptoms. We also quantified changes in adult hippocampal neurogenesis and the 
hypothalamic-pituitary-adrenal (HPA) axis responsiveness to mild stress, both of which are 
implicated in the mechanism of action of classical antidepressants (Lehmann et al., 2013a; 
Santarelli et al., 2003; Schloesser et al., 2010; Surget et al., 2011). We found that ketamine 
had variable effects in depressive and anxiety behaviors depending on the test, as well as 
modest effects on adult hippocampal neurogenesis and HPA-axis output. Taken together, 
these findings demonstrate that a single subanesthetic dose of ketamine has a modest 
therapeutic effect in the SD model when administered following 2 weeks of chronic stress.  
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Materials and Methods 
Mice 
129S6/SvEvTac mice were purchased from Taconic (Hudson, NY) at approximately 8 
weeks of age and tested at 9 weeks of age. C57BL/6J mice (Stock No. 000664) were 
purchased from The Jackson Laboratory (Bar Harbor, ME) at approximately 8 weeks of age 
and tested at approximately 5 months of age. CD-1 mice were purchased from Charles 
River Laboratories (Wilmington, MA) at 8-10 weeks of age and housed individually. CD-1 
mice used in social defeat were approximately 12 weeks of age at the start of the paradigm, 
while CD-1 mice used in the dose titration studies were tested at 9 months of age. Mixed 
strain mice are a mix of 129S/SvEvTac and C57BL/6J and were bred in the New York State 
Psychiatric Institute animal facility. They were tested at 8 weeks of age.  
 
Social Defeat (SD) 
Repeated SD was used to induce a depressive-like phenotype in intruder mice during the 
SD induction phase. Adult aggressor CD-1 male mice were single-housed in a Macrolon® 
polycarbonate resin cages (15.25 in. x 7.8 in x 9.5 in) (Animal Care Systems, Inc., 
Centennial, CO). Male (9 weeks of age) were subsequently placed into the resident CD-1 
mouse’s cage. Three antagonistic encounters were allowed between the CD-1 mouse and 
the intruder. Following the encounters, a polished stainless steel cage divider (Animal Care 
Systems, Inc., Centennial, CO, P/N C79171), which allowed for olfactory and auditory 
communication, but not visual or tactile contact to occur, was placed down the middle to 
separate the two mice. The partition was removed daily for 2 weeks and 3 antagonistic 
encounters were allowed between the mice each day. This procedure consistently yielded a 
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submissive phenotype in the experimental intruder mice. Control (Ctrl) mice were group 
housed in the same cages.  
 
Drugs 
For dose titration studies, mice were administered a single injection of ketamine (10, 30, or 
50 mg/kg) or saline (0.9% NaCl). For the SD study, mice were administered a single 
injection of ketamine (30 mg/kg) or saline (0.9% NaCl) 24 hours following the last session 
of SD.    
 
Forced Swim Test (FST) 
Mice were administered the FST as previously described (Richardson-Jones et al., 2010). 
Briefly, mice were placed into clear plastic buckets 20 cm in diameter and 23 cm deep filled 
2/3 of the way with 22 °C water. All mice were videotaped from the side for 6 min. All mice 
were exposed to the swim test on 2 consecutive days. Scoring was done using an 
automated Viewpoint Videotrack software package. Dependent variables were immobility, 
swimming, and climbing.  
 
Social Interaction (SI) 
Social interaction was performed as previously described (Schloesser et al., 2010) with the 
exception that mice were allowed to explore for 10 min. Sessions were videotaped and 




Elevated Plus Maze (EPM) 
The elevated plus maze was performed as previously described (Saxe et al., 2006).  
 
Novelty Suppressed Feeding (NSF) 
Testing was performed as previously described (David et al., 2007), with the exceptions 
that animals were food restricted for 12 hr and were place in a 40 x 60 cm brightly lit arena 
(1100-1200 lux) with a food pellet placed in the center. Latency of the animals to eat was 
recorded. Immediately after the latency was recorded, the food pellet was removed from 
the arena. The animals were then placed in their home cage and the amount of food 
consumed in 5 min was measured (home cage consumption), followed by an assessment of 
post-restriction weight.  
 
Contextual Fear Conditioning (CFC) 
The 1-shock CFC procedure was performed as previously published (Denny et al., 2012; 
Drew et al., 2010). Mice were placed into the conditioning chamber, received 1 shock at 
180 s (2 s duration, 0.75 mA), and were removed 15 s following the shock. Mice were 
tested for conditioned fear of the training context 24 h following the training session. The 
testing procedure and context were identical to those used on the training day with the 
exception that a shock was not given. Mice were placed into the chamber for 4 min. Both 
sessions were scored for freezing.  
The datasets from context exposure were subjected to a 2 (Treatment: Saline x 
Ketamine) x 4 (Minute) ANOVA with Minute as the repeated measure. Interactions were 
probed using t-tests with the Bonferroni correction. Alpha was set to 0.05 for all analyses.  
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Corticosterone Enzyme Immunoassay (EIA) 
Blood was collected from the retro-orbital sinus from awake mice using hematocrit tubes. 
Blood was then transferred to Eppendorf tubes pre-coated with 5 µl 0.5 M EDTA, placed on 
ice, and immediately spun down to obtain plasma for subsequent EIA. EIA was performed 
using a DetectX Corticosterone EIA Kit (# K014-H1, Arbor Assays).  
 
Immunohistochemistry  
Mice were deeply anesthetized and brains were processed as previously described (Denny 
et al., 2012). Doublecortin (DCX) immunohistochemistry was performed as previously 
described (Denny et al., 2012). Ki67 immunohistochemistry was performed as previously 
described (Scobie et al., 2009).  
 
Cell Quantification  
An investigator blind to treatment used a Zeiss Axioplan-2 upright microscope 
(Oberkochen, Germany) to count cells bilaterally in the granule cell layer of the dentate 
gyrus throughout the entire rostro-caudal axis of the hippocampus (Burghardt et al., 2012; 
Meshi et al., 2006; Santarelli et al., 2003). Every sixth section throughout the entire extent 
of the hippocampus was included in the analysis. Cells were counted bilaterally using the 
20X objective. The average cells per section are presented throughout the text.  






In general, the effect of treamtent or context was analyzed using an ANOVA, using repeated 
measures where appropriate. Significant ANOVAs were follwed up with Fisher’s PLSD tests 
where appropriate. All main effects and interactions are noted in the text.  
All data were analyzed using StatView 5.0 software (SAS Institute, Cary, NC). Alpha 
was set to 0.05 for all analyses. Data are expressed as means + SEM. * p < 0.05, ** p < 0.01, 
*** p < 0.001. 
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Results and Figures 
We hypothesized that ketamine (K) would have a rapid antidepressant effect in mice if 
administered following chronic stress. To control for endogenous resilience, we chose to 
use 129 mice, which, unlike C57Bl/6J mice, are predominantly susceptible to SD stress (see 
Chapter 2) (Denny et al., 2014; Krishnan et al., 2007).  
As an antidepressant dose of ketamine had not previously been established in 129 
mice, we first tested different doses of ketamine in FST to identify a putatively 
antidepressant dose. 129 mice were administered a single injection of saline (Sal) or 10, 30, 
or 50 mg/kg ketamine (K) and tested 1 h later in the FST. Twenty-four hours later, mice 
were placed back into the FST and immobility was assessed. As a positive control, we also 
tested the efficacy of ketamine in the two most commonly used mouse strains in the 
ketamine literature, CD-1 and C57Bl/6J mice, as well as in a mixed strain. In 129 mice, both 
30 and 50 mg/kg K significantly decreased immobility on day 2 of the FST when compared 
to Sal administration [repeated measures ANOVA, dose: F(1,28) = 2.145, p = 0.12; minute: 
F(1,5) = 36.836, p < 0.0001; dose x minute: F(1,15) = 1.703, p = 0.06; planned comparisons 
for minute 1 t-tests: 0 v. 30 mg: p < 0.01; 0 v. 50 mg: p < 0.01] (Figure 3.1A). There was no 
difference in immobility between mice injected with 10 mg/kg K or Sal.  
CD-1 mice have a greater response at baseline to acute ketamine than other strains, 
as measured by FST (da Silva et al., 2010; Owolabi et al., 2014; Popik et al., 2008). Thus, CD-
1s were utilized as a positive control strain for the dose titration studies. We administered 
CD-1 mice a single injection of Sal or K (50 mg/kg) 1 hour prior to day 1 of FST. Mice 
underwent day 2 of FST 24 hours later, and immobility was quantified. There was no 
significant difference in immobility between the groups, though there was a trend for K to 
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decrease immobility in minute 4 of FST [repeated measures ANOVA, dose: F(1,6) = 3.688, p 
= 0.10; minute: F(1,5) = 16.248, p < 0.0001; dose x minute: F(1,5) = 0.714, p = 0.62; planned 
comparisons: minute 4: p = 0.07] (Figure 3.1B). This lack of significant effect is most likely 
due to insufficient power (n = 4).   
We additionally explored the effect of ketamine in baseline C57Bl/6J mice, the 
second most common strain used in the literature. C57Bl/6J mice were given either Sal or K 
(30 mg/kg) 1 hour prior to day 1 of FST. Mice were returned to FST 24 hours later, and 
immobility was measured. There was no difference in immobility between mice injected 
with Sal or K [repeated measures ANOVA, dose: F(1,16) = 0.002, p = 0.96; minute: F(1,5) = 
8.534, p < 0.0001; dose x minute: F(1,5) = 0.584, p = 0.71] (Figure 3.1C). Similarly, there 
was no effect of either 10 mg/kg or 30 mg/kg K in day 2 of FST when administered to a 
mixed strain [repeated measures ANOVA, dose: F(1,14) = 1.047, p = 0.38; minute: F(1,5) = 
13.762, p < 0.0001; dose x minute: F(1,10) = 0.757, p = 0.67] (Figure 3.1D). These findings 
show that different strains have different responses to ketamine at baseline. Additionally, 
these tests identified 30 mg/kg as the lowest dose tested at which ketamine had an effect 
on immobility in day 2 of FST, which is predictive of antidepressant response. 
 
Figure 3.1. Ketamine differentially impacts immobility in the forced swim test in a number of 
strains of mice. (A) Ketamine does not affect immobility at 10 mg/kg, but decreases 
immobility at 30 and 50 mg/kg in 129S6/SvEvTac mice [repeated measures ANOVA, dose: 
F(1,28) = 2.145, p = 0.12; minute: F(1,5) = 36.836, p < 0.0001; dose x min
1.703, p = 0.06; planned comparisons for minute 1 
< 0.01]. (B) K does not significantly 
compared with Sal mice, though there was a trend for K to decrease immobility in minute 4 
of FST [repeated measures ANOVA, dose: 
p < 0.0001; dose x minute: F(1,5) = 0.714, p = 0.62
0.07]. (C) Ketamine does not affect immobility at 30 mg/kg in C57BL/6J mice when 
compared with Sal mice [repeated measures ANOVA, dose: 
minute: F(1,5) = 8.534, p < 0.0001; dose x minute: F(1,5) = 0.584, p = 0.71]
affect immobility at 10 or 30 mg/kg in a mixed strain of mice when compared with Sal mice 
[repeated measures ANOVA, dose: 
0.0001; dose x minute: F(1,10) = 0.757, p = 0.67]
 
Having established 30 mg/kg as our working dose of ketamine, we then went on to 
examine the antidepressant effect of 
behavior. 129 mice were either group housed (Control, Ctrl) or underwent 2 weeks of 
chronic SD housing. Following 2 weeks of SD, mice received a single injection of either Sal 
or K (30 mg/kg) and were tested 2 hours later in day 1 of the FST and retested 24 hours 
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D) K does not 
 
later in day 2 of the FST. Mice were also tested in numerous paradigms to examine the 
effect of ketamine on depressive
Figure 3.2. Experimental paradigm.
housed as Ctrl mice prior to receiving a single injection of Sal or K (30 mg/kg). Two hours 
after receiving an injection, they were tested in forced swim (FST). They were then 
subsequently tested in social int
novelty suppressed feeding (NSF) (48 
hours post-injection), trained in contextual fear conditioning (CFC) on the 4
injection, re-exposed to the CFC chamber on the 5
1 week post-injection.  
 
There is a trend for a modest antidepressant effect of k
social defeat in the forced swim 
Ctrl and SD mice were administered Sal or 
hours later, as behavior on day 2 of FST is generally considered more indicative of 
depressive behavior than day 1 
Ctrl, K showed comparable levels of immobility in 
F(1,28) = 0.027, p = 0.87; minute: F(1,5) = 23.396, p < 0.0001; drug x minute: F(1,5) = 
0.190, p = 0.97] (Figure 3.3A). SD, Sal and SD, K also showed similar levels of immobility
though there was a trend for ketamine to decrease immobility in the first 2 minutes of FST
[repeated measures ANOVA, drug: 
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-like, anxiety, and cognitive behavior. 
 Mice underwent two weeks of SD or were group 
eraction (SI), day 2 of FST (24 hours post-injection), 
hours post-injection), elevated plus maze (EPM) (72 
th day post-injection, and sacrificed (Sac) 
etamine administration following 
test 
K (30 mg/kg) and assessed on day 2
(Porsolt et al., 1978a; Porsolt et al., 1978b). Ctrl, Sal and 
FST [repeated measures ANOVA, drug: 
F(1,24) = 1.198, p = 0.28; minute: F(1,5) = 35.512, p < 
 
th day post-




0.0001; drug x minute: F(1,5) = 1.931, p = 0.09
minute 2: p = 0.16] (Figure 3.3
 
Figure 3.3. There is a trend for k
Twenty-four hours following an injection of
FST. Ctrl, Sal and Ctrl, K mice did not differ from each other [repeated measures ANOVA, 
drug: F(1,28) = 0.027, p = 0.87; minute: F(1,5) = 23.396, p < 0.0001; drug x minute: F(1,5) = 
0.190, p = 0.97]. (B) SD, K and SD, Sal mice 
immobility, though there was a trend for K to decrease immobility in the first 2 minutes of 
FST [repeated measures ANOVA, drug: 
< 0.0001; drug x minute: F(1,5) = 1.931, p = 0.09




; planned comparisons: minute 1: p = 0.13; 
B).  
etamine to decrease stress-induced immobility in FST
 Sal or K, mice were administered day 2 of the 
did not display significantly different
F(1,24) = 1.198, p = 0.28; minute: F(1,5) = 35.512, p 




 levels of 
 SEM. 
 
Stress-induced decreases in distance traveled in social interaction is partially rescued by 
ketamine 
In SI, SD mice are given the option to interact with a control object or the dominant CD
with which they were co-housed, or to explore the open field are
conducted. Ctrl mice are given the same options, but have not had previous contact with 
the CD-1. Avoidance of the CD-1 and decreased exploration of the chamber are usually 
viewed as the most sensitive measures of SD
et al., 2010).  
SD mice traveled less than Ctrl mice during the first 5 minutes of the social 
interaction test, a measure of decreased exploration 
decreased distance traveled in 
traveled in the SD mice (SD, K) when compared to SD, Sal mice 
0.05) (Figure 3.4B). These data suggest that SD was effective in inducing depressive
behavior in these mice, and that ketamine had onl
 
Figure 3.4. Ketamine increases distance traveled in social defeat mice during the social 
interaction (SI) paradigm. (A) SD mice traveled less when compared with Ctrl mice during 
the first 5 minutes (p < 0.0001)
0.001). K increased distance traveled during the second 5 minutes of the SI paradigm in the 
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na in which the test is 
-induced depressive-like behavior 
(p < 0.0001) (Figure 3.4A
the second 5 minutes (p < 0.001), but K increased distance 
in the last 5 minutes 
y a modest rescue effect on that behavior.
 and (B) the second 5 minutes of the SI paradigm (p < 
-1 
(Schloesser 






SD, K mice when compared with SD, Sal mice (p < 0.05). (n = 12
Error bars represent + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
Ketamine robustly decreases anxiety in NSF in control mic
obscured by stress-induced metabolic changes
Though ketamine had no substantial 
depressive-like behavior in SD mice, it is possible that it has divergent effects on other 
symptom clusters, such as anxiety or cognitive impairments. In order to test the effect of 
ketamine on stress-induced anxi
(NSF), a conflict test between two competing drives; hunger and fear. In order to determine 
differences in anxiety levels in NSF, hunger drive must be the same in all groups. To this 
end, several dimensions of metabolism and hunger must be compared in addition to the 
main measure of latency to feed. Prior to starting NSF, we first confirmed that there was no 
difference in body weights between the
 
Figure 3.5. Social defeat does not affect body weight
body weight between the groups (p’s > 0.5
represent + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.
 
Having confirmed that mice were of equivalent weight at the beginning the test, mice were 
then fasted for 12 hours. Following the 12 hours fast, mice were placed in a brightly lit 
arena with a pellet in the center and latency to feed was recorded. Ketamine significantly 
62 
-15 male mice per group). 
 
e, but in SD mice this effect may be
 
baseline effect and only modestly impacted 
ety, we tested the mice in novelty suppressed feeding 
 groups following SD (p’s > 0.5) (Figure 3.5
 
. There was no significant difference in 





decreased latency to feed in Ctrl mice (Ctrl, K) compared to Sal (Ctrl, Sal), indicative of 
decreased anxiety (Mantel-Cox log rank text: p = 0.02) (Figure 3.6A). K did not, however, 
impact latency to feed in SD mice (SD, Sal vs. SD, K: Mantel-Cox log rank text: p = 0.02) 
(Figure 3.6A). Unexpectedly, this was not because SD mice displayed increased hesitancy 
to approach the pellet. Instead, similar to Ctrl, K mice (p = 0.01), SD, Sal mice (p < 0.001) 
and SD, K mice (p < 0.05) had shorter average latencies to feed than Ctrl, Sal mice (Figure 
3.6B). The anxiety interpretation of the SD data is confounded by the fact that SD mice 
show increased home cage food intake when compared to Ctrl mice as measured by pellet 
consumption in the home cage, a non-anxiogenic environment (p = 0.03) (Figure 3.6C). 
Though there was no significant difference in weight between the groups before and after 
NSF (p’s > 0.5) (Figure 3.6D), SD mice lost 25% more weight than Ctrl mice during the 12-
hr fast (p < 0.0001) (Figure 3.6E). This is indicative of a stress-induced metabolic change 
in the SD group that is not rescued by ketamine. We also looked weight loss due to stress-
induced hypophagia, which is influenced by affective state, not metabolic state. 
Interestingly, though SD, Sal mice still lost more weight than controls (Ctrl, Sal vs SD, Sal: p 
= 0.02), ketamine was able to rescue this effect (SD, Sal vs SD, K: p = 0.04) (Figure 3.6F). 
Taken together, these findings suggest that ketamine is anxiolytic in NSF and stress-
induced hypophagia, but does not impact SD-induced metabolic changes in 129 mice. 
 
 
Figure 3.6. Ketamine decreases latency to feed in NSF in control mice, but has no effect in 
social defeat mice. (A) Ctrl, K mice displayed a shorter latency to approach the pellet than 
Ctrl, Sal mice (Mantel-Cox log rank text: p = 0.02). SD, Sal and SD, K mice had equivalent 
latencies (Mantel-cox log rank test: p = 0.57). (
mice (p = 0.01), SD, Sal mice (p < 0.001), and SD, K mice (p < 0.05) had a red
latency to approach the pellet. (
than the Ctrl mice (p = 0.03). (D
between the groups before NSF or after NSF. (p’s > 0.5). 
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B) In comparison to Ctrl, Sal mice, Ctrl, K 
C) SD mice consumed more of the pellet in the h
) There was no significant difference in body weight 





weight than Ctrl mice while fasting for the NSF paradigm (p < 0.0001). (
more weight than Ctrl, Sal mice following the start of behavioral testing, indicative of 
higher levels of stress-induced hypophagia (p = 0
loss in SD mice when compared to Sal treatment (p = 0.04). (n = 12
group). Error bars represent + 
 
Ketamine does not decrease distance traveled in the ele
We additionally tested mice in elevated plus maze (EPM), another conflict choice test that 
can be used to measure anxiety. In this test, mice are given the choice to explore the open 
arms or to remain in the less anxiogenic closed arms of t
was the same across groups in the EPM (p’s > 0.05) (
supports that the decreased exploration observed in the SD mice in the SI task is reflective 
of a change in affective state, and not due
the EPM, all groups spent equivalent amount of time in the closed, i.e. safe, arms (p’s > 
0.05) (Figure 3.7B). Compared to Ctrl, Sal mice, Ctrl, K mice spent less time in the open 
arms (p = 0.04), but there was no main effect of defeat stress and no difference between SD 
groups (p’s > 0.05) (Figure 3.7C
whether or not ketamine is capable of reducing stress
to be determined. 
 
Figure 3.7. Ketamine does not impact locomotion in the elevated plus maze
distance and (B) time in closed did not differ between the groups (p’s > 0.05). (
mice spent less time in the open arms when compared with the Ctrl, Sal mice (p = 0.04). (n 
= 12-15 male mice per group). Error bars represent 
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F) SD, Sal mice lost 
.02). K decreased the amount of weight 
-15 male mice per 
SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.  
vated plus maze 
he maze. Total distance traveled 
Figure 3.7A). This finding further 
 to ketamine-induced changes in locomotion. In 
). As SD did not increase anxiety in EPM in this cohort, 
-induced anxiety in this test remains 
. (
+ SEM. * p < 0.05. 
 
A) Total 
C) Ctrl, K 
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Ketamine reduces freezing in SD mice in contextual fear conditioning  
Having seen a modest effect of ketamine on depressive-like behavior, a more robust effect 
on anxiety behavior, and no effect on stress-induced metabolic changes, we then went on to 
examine the effect of ketamine on cognition, a major aspect of psychiatric disorders that is 
often overlooked in animal studies.  
To assess the effect of ketamine on stress-induced cognitive deficits, we used a 1-
shock contextual fear conditioning (CFC) paradigm (Denny et al., 2012; Drew et al., 2010), 
having previously shown that SD mice are impaired in this task (see Chapter 2) (Denny et 
al., 2014). There was no difference between groups during training on day 1 of CFC in 
either freezing before the shock [Ctrl, Sal vs. Ctrl, K: repeated measures ANOVA, drug: 
F(1,28) = 1.050, p = 0.31; minute: F(1,2) = 1.105, p = 0.34; drug x minute: F(1,2) = 0.368, p 
= 0.69. SD, Sal vs. SD, K: repeated measures ANOVA, drug: F(1,24) = 0.012, p = 0.91; minute: 
F(1,2) = 6.198, p < 0.01; drug x minute: F(1,2) = 0.522, p = 0.60] (Figure 3.8A) or after the 
shock (p’s > 0.05) (Figure 3.8B). When mice were re-exposed to the fearful context, there 
was no difference in context-elicited fear between Ctrl, Sal and Ctrl, K mice [repeated 
measures ANOVA, drug: F(1,28) = 0.224, p = 0.64; minute: F(1,3) = 31.787, p < 0.0001; drug 
x minute: F(1,3) = 0.317, p = 0.82] (Figure 3.8C). SD, K mice showed less context-elicited 
fear than SD, Sal mice [repeated measures ANOVA, drug: F(1,24) = 5.976, p = 0.02; minute: 
F(1,3) = 13.858, p < 0.0001; drug x minute: F(1,3) = 1.450, p = 0.24; planned comparisons: 
120-180s: p = 0.06; 180s-240s: p < 0.05] (Figure 3.8C). This once again suggests that 
ketamine may be an effective anxiolytic in mice. As SD mice are more anxious than Ctrl 
mice, their freezing may be a combination of generalized anxiety and specific contextual 
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fear expression. If ketamine decreases general anxiety but not specific fear memory 
expression, this could explain why ketamine only effects freezing in SD mice in CFC.  
Since we did not see a social defeat-induced cognitive deficit in 1-shock CFC in this 
cohort, we were not able to assess the impact of ketamine on cognitive impairment. 
 
Figure 3.8. Ketamine reduces context
K mice had comparable levels of freezing before the shock during CFC training [repeated 
measures ANOVA, drug: F(1,28) = 1.050, p = 0.31; minute: F(1,2) = 1.105, p = 0.34; drug x 
minute: F(1,2) = 0.368, p = 0.69]. 
before the shock during CFC training [repeated measures ANOVA, drug: 
= 0.91; minute: F(1,2) = 6.198, p < 0.01; drug x minute: F(1,2) = 0.522, p = 0.60].
groups did not differ in freezing levels
K mice expressed comparable levels of context
F(1,28) = 0.224, p = 0.64; minute: F(1,3) = 31.787, p < 0.0001; drug x minute: F(1,3) = 
0.317, p = 0.82]. SD, K expressed less context
mice [repeated measures ANOVA, drug: 
p < 0.0001; drug x minute: F(1,3) = 1.450, p = 0.24; planned comparisons: 120
0.06; 180s-240s: p < 0.05]. (n = 12
p < 0.05.  
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-elicited fear in social defeat mice. (A) Ctrl, Sal and Ctrl, 
SD, Sal and SD, K mice had comparable levels of freezing 
F(1,24) = 0.012, p 
 following the shock (p’s > 0.05). (C) Ctrl, Sal and Ctrl, 
-elicited [repeated measures ANOVA, drug: 
-elicited fear when compared with SD, Ctrl 
F(1,24) = 5.976, p = 0.02; minute: F(1,3) = 13.858, 
-15 male mice per group). Error bars represent 
 
 (B) All 
-180s: p = 
+ SEM. * 
 
 
Ketamine increases hippocampal neuronal proliferation
We explored the impact of subanesthetic
process implicated in the mechanism of action of classical antidepressants 
2003). We measured levels of neuronal proliferation in the dentate gyrus
of the hippocampus in which ongoing adult 
staining for Ki67, a marker of cell division. Ketamine significantly increased 
Ki67+ cells compared to Sal (p < 0.01)
cells in Ctrl, K mice compared to 
Ki67+ cells in SD, K mice compared to SD, Sal mice (p = 0.1
have an effect on doublecortin (DCX), a marker of 
was no notable increase in early
0.05) (Figure 3.9B).  
 
Figure 3.9. Ketamine increases proliferation of hippocampal neural progenitor cells in the 
dentate gyrus. (A) K mice had significantly more Ki6
mice had significantly higher levels of Ki67+ cells per hippocampal section
mice (p = 0.03). There was a trend for increased Ki67 expression in SD, K mice compared 
SD, Sal mice (p = 0.16). (B) DCX levels 
12-15 male mice per group). Error bars represent 
69 
 
 ketamine on adult hippocampal neurogenesis, a 
(Santarelli et al., 
 (DG)
hippocampal neurogenesis takes place, by 
 (Figure 3.9A). There were significantly more Ki67+ 
Ctrl, Sal mice (p = 0.03) and a trend for significantly more 
6). Ketamine did not, however, 
immature neurons, suggesting that there 
-stage survival or induction of rapid maturation (p’s > 
7+ cells than Sal mice (p < 0.01
 than Ctrl, Sal 
did not differ between the groups (p’s > 0.05). (n = 
+ SEM. * p < 0.05.  
, the region 
the number of 




Ketamine may improve HPA-axis responsiveness following chronic stress 
The HPA-axis is also known to be dysregulated by chronic stress (Lehmann et al., 2013a; 
Surget et al., 2011). Corticosterone is the main output of the HPA-axis, and the primary 
hormone that regulates physiological and behavioral responses to stress (Goldstein, 2010). 
Depending on the paradigm, SD stress can increase basal corticosterone levels and blunt 
HPA-axis responsiveness to subsequent stressors (Lehmann et al., 2013a). In order to test 
HPA-axis responsiveness, we exposed mice to a novel cage, a mild stressor, and measured 
corticosterone levels 30 minutes after the beginning of exposure. There was a trend for SD, 
Sal mice to have less elevated corticosterone levels following mild stress when compared to 
Ctrl, Sal mice (p = 0.06) (Figure 3.10A). Additionally, there was trend for SD, K mice to 
have a less blunted corticosterone response than SD, Sal mice (p = 0.06) (Figure 3.10B). 
Though these experiments need to be repeated and expanded upon, this data suggests that 
subanesthetic ketamine may be capable of rapidly restoring HPA-axis functionality 
following chronic stress. 
 
 
Figure 3.10. Ketamine may rescue SD
stress. There was a trend for SD, Sal mice to have a blunted corticosterone response to a 
mild stressor compared to Ctrl, Sal mice (p = 0.06




-induced impairments in HPA-axis responsiveness to 
). There was a trend for SD, K mice to 
when compared to SD, Sal mice (p 
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Discussion 
In this study, we show that different strains respond differently at baseline to acute 
ketamine administration. In these experiments, we show that ketamine has a modest 
antidepressant effect in 129S6/SvEvTac mice when administered following 2 weeks 
chronic SD stress. Ketamine did not have a significant effect in day 2 of FST, but this may be 
because SD did not induce a large increase in FST immobility in this cohort. Ketamine 
partially rescued SD-induced decreases in distance traveled in the SI task, but only in the 
second 5 minutes of this test. Ketamine did not alter distance traveled in EPM, suggesting 
that the ketamine-induced increase in distance traveled in SI is due to the drug’s 
antidepressant effect, and not a non-specific induction of hyperactivity.  
Taken together, though this data demonstrates that ketamine has a rapid-onset 
antidepressant effect in mice, the effect is notably more modest than what is reported 
clinically. As the half-life of ketamine is very short, in the clinic ketamine is administered 
over several hours by slow i.v. infusion to maximize efficacy (Murrough et al., 2013a; 
Murrough et al., 2013b; Zarate et al., 2006). It is possible that a similar delivery approach, 
as opposed to a single bolus injection, would improve antidepressant response in mice. 
Overall, acute ketamine appears to be a better anxiolytic than an antidepressant, 
which is somewhat surprising considering contradictory evidence in the clinical and pre-
clinical literature. Though ketamine did not impact anxiety behavior as measured by EPM, 
this is possibly because SD did not robustly increase anxiety in this task in this cohort. 
Ketamine had a robust anxiolytic effect in NSF in Ctrl mice, significantly decreasing latency 
to feed. Interpretation of the effect of ketamine on NSF in SD mice is less clear, as the 
measurement of anxiety in these mice is confounded by stress-induced metabolic changes 
 73 
that appear to have increased their hunger drive. Ketamine did not impact this SD-induced 
change in metabolism. Ketamine did, however, rescue the exaggerated stress-induced 
hypophagia exhibited by SD mice.  
Chronic treatment with classical antidepressants restores both metabolic and 
immune abnormalities (Frick et al., 2009; Surget et al., 2011), which had previously 
suggested a convergent mechanism of these disease processes in affective disorders. The 
divergent effect of ketamine on stress-induced depressive behavior and metabolic changes, 
however, suggests that the relationship between mood-states and the periphery in 
antidepressant treatment needs to be revisited. 
In addition to the affective dimensions of depressive-like and anxiety behavior, we 
attempted to examine the effect of ketamine on cognition. Unfortunately, because we did 
not see a stress-induced cognitive deficit in 1-shock CFC in this study, whether ketamine 
can improve cognitive impairment in affective disorders remains to be determined. Our 
previous experiments identified a robust SD-induced deficit in 1-shock CFC memory when 
recall was assessed 5 days after training. In this experiment, mice were re-exposed to the 
conditioned context only 24 hrs post-training. Mice were tested at this time-point to allow 
for assessment of neuronal proliferation in the DG within 1 week of the initial ketamine 
injection. It is likely we did not see a stress-induced CFC deficit in this cohort as we were 
testing a short-term memory relative to the more long-term memory assessed in the 5-day 
delay paradigm. Future studies are necessary to determine if ketamine can rescue the more 
long-term memory deficit identified in Chapter 2. Though we were unable to assess the 
impact of ketamine on stress-induced cognitive impairment, ketamine did, however, 
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decrease context-elicited fear in 1-shock CFC in SD mice, further supporting the putative 
anxiolytic effects of ketamine.  
In terms of the cellular and molecular changes most commonly associated with 
affective disorders, altered adult hippocampal neurogenesis and dysregulated HPA-axis 
output, ketamine significantly increased hippocampal neural proliferation as measured by 
Ki67 in Ctrl mice, and there was a trend for ketamine to both increase proliferation and 
restore HPA-axis responsiveness to stress in SD mice. Though we did not observe an effect 
on number of DCX+ cells, this could be for several possible reasons. For example, ketamine 
may not increase proliferation until several days post-injection, which would not yet be 
observable by DCX counts, or might preferentially increase proliferation of non-neuronal 
cells (DCX-). Alternatively, ketamine may also induce rapid maturation of young adult-born 
neurons to a stage where they no longer express DCX. This maturation-induced depletion 
of DCX+ cells would counterbalance the proliferative increase, resulting in no detectable 
net difference in DCX+ cell number. 
Though ketamine increased cellular proliferation in the DG, it is unlikely that this 
effect underlies ketamine’s mechanism of action (MOA). Ketamine’s antidepressant effect is 
too rapid to allow the necessary time for these newborn cells to have a functional impact 
on hippocampal circuitry (Denny et al., 2012). It is possible that other changes in adult 
hippocampal neurogenesis—such as survival, rapid maturation, or dematuration—may 
contribute to ketamine’s rapid-antidepressant effect. An absence of an effect of ketamine 
on DCX does not rule out the possible requirement of intact adult hippocampal 
neurogenesis. In fact, the large effect of ketamine on NSF, a task known to be adult 
hippocampal neurogenesis-dependent, suggests that adult hippocampal neurogenesis may 
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be involved in ketamine’s MOA. Future studies quantifying the impact of acute 
subanesthetic ketamine on survival, rapid maturation, and dematuration of adult-born 
hippocampal neurons will provide further insight into the role of neurogenesis in 
ketamine’s MOA. Moreover, studies in which the neurogenic niche is disrupted (e.g., via x-
irradiation or targeted genetic methods) will be most informative as to whether or not 
intact adult hippocampal neurogenesis is required for ketamine’s antidepressant effect.  
It is also possible that the induction of ketamine’s antidepressant effect and its 
maintenance occur through different mechanisms. For example, the initial induction of the 
antidepressant effect may occur downstream of the HPC entirely, perhaps by ketamine 
acting directly on the prefrontal cortex, while maintenance of the effect after the washout 
period could be sustained by circuit-level changes in the HPC. 
In order for the cellular and molecular mechanisms underlying ketamine’s MOA to 
be accurately identified, it is essential that researchers utilize models in which they have 
established a true antidepressant response. As clear from the experiments described here, 
as well as a critical review of the murine ketamine literature, this is a non-trivial task. It is 
possible that the molecules and receptors previously identified in the literature as required 
or unnecessary may only be so for the predictive effect of ketamine on FST immobility, and 
not necessarily indicative of their actual role in the antidepressant effect of ketamine.  
Taken together, these findings suggest that the study of ketamine in mouse models 
is not as straightforward as has been presented in the literature. The responsiveness of 
different strains and different tests is far more variable than previously emphasized. 
Moving forward, it is essential that these factors be taken into consideration during 
experimental design. Belzung and Lemoine identify homological validity, a subcategory of 
 76 
construct validity, as an critical aspect of psychiatric model validation (Belzung and 
Lemoine, 2011). Homological validity is determined by the choice of a specific species and 
strain for use in a given model. Though the 129 strain has been shown to respond at 
baseline to classical antidepressants (Santarelli et al., 2003), C57Bl/6J mice only show an 
antidepressant response following chronic stress. Thus, non-stressed C57Bl/6J mice are 
not a homologically valid model for the study of the antidepressant effects of ketamine. 
Recognizing these and other dose, strain, and paradigm considerations is essential for the 
optimization of mouse models of the antidepressant effects of ketamine. 
Identifying the MOA underlying the rapid-onset antidepressant effect of ketamine 
has the potential to inform not just novel drug development, but also our understanding of 
the pathophysiology of depression. The use of ketamine as an antidepressant in mice, much 
like any new tool, comes with its own set of challenges. Through thorough characterization 
and consideration of which behavioral paradigms to employ, the study of ketamine in 
animal models has the potential to lead to breakthroughs in both our understanding and 





















Stress commonly precipitates psychiatric illness, particularly in vulnerable 
populations. For example, 1 in 5 soldiers returns from combat with post-traumatic stress 
disorder (PTSD), combat-associated major depressive disorder (MDD), or both (Tanielian 
and Rand Corporation, 2008). Perhaps more surprising, however, is that 4 out of 5 soldiers 
do not develop psychopathology. While there has been extensive research on factors 
promoting susceptibility to psychiatric illnesses, few studies have examined what makes 
individuals resistant. This ability to adapt to stress without developing psychopathology is 
known as stress resilience. Until recently, the sparse research on stress resilience has been 
predicated on the assumption that resilience is a passive property—more or less the 
absence of the risk factors that make individuals susceptible to stress-induced pathology 
(see Russo et al., 2012 for review). Recent work in animal models, however, suggests that 
the neurobiology of stress resilience is mediated through active processes, and often 
distinct, parallel mechanisms to those of susceptibility (Chaudhury et al., 2013; Krishnan et 
al., 2007; Walsh et al., 2014).  
 The idea that increasing stress resilience could protect against the development of 
psychiatric disorders is an appealing one, but treatments to increase resilience are still in 
their infancy. Current interventions fall predominantly on the behavioral side, with 
psychotherapy, exercise, and stress inoculation—mild stress exposure to promote adaptive 
coping to subsequent severe stress (Levine, 1957; Lyons and Parker, 2007)—being the best 
available tools to increase resilience clinically (Meredith, 2011). Rodent studies also 
suggest a role for exercise and enriched environment in stress resilience (Lehmann and 
Herkenham, 2011; Schloesser et al., 2010; Schoenfeld et al., 2013). Beyond behavioral 
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manipulations in mice, researchers have successfully increased resilience biochemically 
through viral and transgenic overexpression methods (Donahue et al., 2014), optogenetic 
activation (Chaudhury et al., 2013), and chronic blockade of stress hormones (Lehmann et 
al., 2013a; Lehmann et al., 2013c). However, none of these interventions is directly 
translatable to the clinic. Whether any of our existing antidepressants are distantly capable 
of increasing resilience, however, is yet to be explored.  
 Antidepressants are typically used to treat existing depressive symptoms, but 
chronic antidepressant treatment also protects against subsequent depressive episodes 
(Doogan and Caillard, 1992; Keller and Boland, 1998; Montgomery et al., 1988; 
Montgomery and Dunbar, 1993; Montgomery et al., 1993). Maintenance treatment in MDD 
patients is often referred to as prophylaxis against the development of additional 
depressive episodes (Frank et al., 1991). Whether this prophylactic effect against 
symptomatic episodes in disordered individuals extrapolates out to preventing de novo 
psychiatric disorders remains to be tested. 
 Ketamine, a rapid-acting antidepressant, has been shown to have antidepressant 
effects as rapidly as 2 hours following a single subanesthetic injection (Zarate et al., 2006). 
Whereas classical antidepressants require ongoing daily administration to maintain 
therapeutic efficacy, ketamine has the benefit of being administered medically as a single 
dose (Murrough et al., 2013b; Zarate et al., 2006). Because a single dose of ketamine has a 
window of therapeutic efficacy far beyond its half-life of a few hours (Idvall et al., 1979; 
Murrough et al., 2013b; Zarate et al., 2006), it is an excellent candidate for a plausible 
clinical approach to pharmacologically increasing stress resilience. Whether ketamine 
induces stress resilience at all, however, has yet to be tested. 
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  Therefore, in order to examine whether ketamine could increase stress resilience 
and thereby, possibly, protect against de novo induction of psychopathology, we utilized a 
social defeat (SD) paradigm to induce depressive-like behavior in mice. We chose to 
perform SD in a 129S6/SvEvTac strain, which robustly and reliably develops a depressive-
like phenotype following SD (Denny et al., 2014). Mice were administered a single 
subanesthetic injection of either saline (Sal) or ketamine (K) and one week later, SD was 
administered to half of the mice. After two weeks of SD, mice were tested in a number of 
behavioral paradigms to assess whether ketamine was able to protect against stress-
induced depression-like behaviors. We tested experimental mice both in depressive-like 
behaviors and anxiety-related behaviors. We found that a single injection of ketamine 
induced robust stress resilience that persisted for at least 3 weeks post-injection. To our 
knowledge, this is the first study to examine the potential of ketamine to provide long-term 




Materials and Methods 
Mice 
129S6/SvEvTac mice were purchased from Taconic (Hudson, NY) at approximately 8 
weeks of age. CD-1 mice were purchased from Charles River Laboratories (Wilmington, 
MA) at 8-10 weeks of age and housed individually. Mice were housed 4 to 5 per cage in a 
12-h (06:00-18:00) light-dark colony room at 22°C. Food and water were provided ad 
libitum. Behavioral testing was performed during the light phase. The procedures 
described herein were conducted in accordance with the National Institutes of Health 
regulations and approved by the Institutional Animal Care and Use Committees of 
Columbia University and the New York State Psychiatric Institute.  
 
Drugs 
Mice were administered a single injection of saline (0.9% NaCl) or ketamine (30 mg/kg) 
(Ketaset III, Ketamine HCl injection, Fort Dodge Animal Health, Forth Dodge, IA) 1 week 
before the start of social defeat (SD).   
 
Social Defeat (SD) 
Repeated SD was used to induce a depressive-like phenotype in intruder mice as previously 
described (Denny et al., 2014). Briefly, adult aggressor CD-1 male mice were single-housed 
in Macrolon® polycarbonate resin cages (15.25 in. x 7.8 in x 9.5 in) (Animal Care Systems, 
Inc., Centennial, CO). Male 129S6/SvEvTac mice (9 weeks of age) were subsequently placed 
into the resident CD-1 mouse’s cage. Three antagonistic encounters were allowed between 
 82 
the CD-1 mouse and the intruder. Following the encounters, mice were separated by a 
polished stainless steel cage divider (Animal Care Systems, Inc., Centennial, CO, P/N 
C79171), which allowed for olfactory and auditory communication, but limited visual or 
tactile contact. The partition was removed daily for 2 weeks and 3 antagonistic encounters 
were allowed between the mice each day. This procedure consistently yielded a submissive 
phenotype in the experimental intruder mice. Control (Ctrl) mice were group housed in the 
Macrolon® polycarbonate resin cages without dividers.  
 
Forced Swim Test (FST) 
Mice were administered the FST as previously described (Richardson-Jones et al., 2010). 
Briefly, mice were placed into clear plastic buckets 20 cm in diameter and 23 cm deep filled 
2/3 of the way with 22°C water. Mice were videotaped from the side for 6 min and were 
exposed to the swim test on 2 consecutive days. Scoring was performed using an 
automated Viewpoint Videotrack software package. Dependent variables were immobility, 
swimming, and climbing.  
 
Social Interaction (SI) 
Social interaction was performed as previously described (Schloesser et al., 2010). Briefly, 
mice were placed into a large open field containing 2 upside-down wire mesh pencil cups. 
One pencil cup served as a novel object or empty container. The other pencil cup contained 
the CD-1 aggressor mouse. Mice were placed in the middle of the open field arena and 
allowed to explore for 10 minutes. Sessions were videotaped and the first 5 min were later 
analyzed using behavioral tracking software (TopScan, CleverSys, Reston, VA).  
 83 
Novelty Suppressed Feeding (NSF) 
Testing was performed as previously described (David et al., 2007), with the exceptions 
that animals were food restricted for 12 hours and were place in a 40 x 60 cm brightly lit 
arena (1100-1200 lux) with a food pellet placed in the center. Latency of the animals to 
begin eating was recorded. Immediately after the latency was recorded, the food pellet was 
removed from the arena. The animals were then placed into a cage and the amount of food 
consumed in 5 min was measured (home cage consumption), followed by an assessment of 
post-restriction weight.  
 
Elevated Plus Maze 
The elevated plus maze was performed as previously described (Saxe et al., 2006).  
 
Contextual Fear Conditioning (CFC) 
The 1-shock CFC procedure was performed as previously published (Denny et al., 2012; 
Drew et al., 2010). For the 1-shock CFC paradigm, mice were placed into the conditioning 
chamber, received 1 shock at 180 s (2 s, 0.75 mA), and were removed 15 s following the 
shock. Mice were tested for conditioned fear of the training context 24 h following the 
training session. The testing procedure and context were identical to those used on the 
training day with the exception that a shock was not given. Mice were placed into the 
chamber for 4 min. Both sessions were scored for freezing.  
The datasets from context exposure were subjected to a 2 (Treatment: Saline x 
Ketamine) x 4 (Minute) ANOVA with Minute as the repeated measure. Interactions were 




Mice were deeply anesthetized and brains were processed as previously described (Denny 
et al., 2012). Doublecortin (DCX) immunohistochemistry was performed as previously 
described (Denny et al., 2012). Ki67 immunohistochemistry was performed as previously 
described (Scobie et al., 2009).  
 
Cell Quantification  
An investigator blind to treatment used a Zeiss Axioplan-2 upright microscope 
(Oberkochen, Germany) to count cells bilaterally in the granule cell layer (GCL) of the 
dentate gyrus (DG) throughout the entire rostro-caudal axis of the hippocampus (HPC) 
(Burghardt et al., 2012; Meshi et al., 2006; Santarelli et al., 2003). Every sixth section 
throughout the entire extent of the HPC was included in the analysis. Cells were counted 
bilaterally using a 20X objective. The average cells per section are presented throughout 
the text.  
   
Statistical Analysis 
In general, the effect of treamtent or context was analyzed using an ANOVA, using repeated 
measures where appropriate. Significant ANOVAs were follwed up with Fisher’s PLSD tests 
where appropriate. All main effects and interactions are noted throughout the text.  
All data were analyzed using StatView 5.0 software (SAS Institute, Cary, NC). Alpha 
was set to 0.05 for all analyses. Data are expressed as means + SEM. * p < 0.05, ** p < 0.01, 
*** p < 0.001.  
 
Results and Figures 
We hypothesized that ketamine (K) would confer stress
prior to stress. To test this hypothesis, mice were injected with a single injection of saline 
(Sal) or K (30 mg/kg) (Figure 4.
studies indicated that this dose did n
not shown). One week following the single injection of ketamine, mice either remained in 
group housing (Control, Ctrl) or were administered a social d
depressive-like behavior. After 2 weeks of SD, mice were administered a number of 
behavioral paradigms to test for depressive
impairment. Mice were sacrificed 4 weeks after the initial injection of Sal or K. 
 
Figure 4.1. Experimental paradigm.
(30 mg/kg). One week later, they were then administered a social defeat (SD) paradigm, 
which lasted 2 weeks. Twenty-
swim (FST). They were then subsequently te
weeks post-injection), novelty suppressed feeding (NSF) (24 days post
plus maze (EPM) (25 days post
the 26th day post-injection, re-exposed to 
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Ketamine administration prior to social defeat protects against the induction of depressive-
like behavior  
The forced swim test (FST) is one of the most commonly used measures of antidepressant 
efficacy (Holmes, 2003; Petit-Demouliere et al., 2005). In fact, many papers exploring the 
effects of ketamine in mouse models only observe effects in the FST (Ghasemi et al., 2010; 
Lindholm et al., 2012; Liu et al., 2012). In our study, we found no difference in immobility 
between Ctrl mice administered saline (Ctrl, Sal) and Ctrl mice administered ketamine 
(Ctrl, K) on day one of the FST [repeated measures ANOVA, drug: F(1,28) = 0.268, p = 0.61; 
minute: F(1,5) = 22.450, p < 0.0001; drug x minute: F(1,5) = 1.189, p = 0.32] (Figure 4.2A). 
Likewise, there was no difference in immobility between SD mice injected with saline (SD, 
Sal) or SD mice injected with ketamine (SD, K) on day 1 [repeated measures ANOVA, drug: 
F(1,26) = 0.693, p = 0.41; minute: F(1,5) = 19.898, p < 0.0001; drug x minute: F(1,5) = 
0.746, p = 0.59] (Figure 4.2B). Minutes 3-6 are often used as the variable measure in this 
test because this is when animals “give up” and also, where the effects of antidepressants 
are often the most robust. There was no difference in average immobility time for minutes 
3-6 across all groups, independent of drug or housing conditions, on day 1 of the FST 
[ANOVA, condition: F(1,1) = 2.422, p = 0.13; drug: F(1,1) = 0.004, p = 0.95; condition x drug: 
F(1,1) = 0.258, p = 0.61] (Figure 4.2C). 
Classically, immobility on day 2 of the FST has been interpreted as an increase in 
hopelessness or a negative mood (Porsolt et al., 1978a). On day 2 of the FST, Ctrl, Sal and 
Ctrl, K displayed equal levels of immobility [repeated measures ANOVA, drug: F(1,28) = 
0.004, p = 0.95; minute: F(1,5) = 0.362, p < 0.0001; drug x minute: F(1,5) = 0.362, p = 0.87] 
(Figure 4.2D). In SD mice, prior treatment with ketamine (SD, K) significantly decreased 
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immobility when compared with saline (SD, Sal) [repeated measures ANOVA, drug: F(1,21) 
= 8.094, p < 0.01; minute: F(1,5) = 6.949, p < 0.0001; drug x minute: F(1,5) = 0.367, p = 
0.87; planned comparisons, p’s = 0.08, 0.04, 0.01, 0.01, 0.02, 0.02 for minutes 1, 2, 3, 4, 5, 
and 6, respectively] (Figure 4.2E). For minutes 3-6, there were differences in average 
immobility [ANOVA, condition: F(1, 1) = 6.294, p = 0.02; drug: F(1,1) = 2.789, p = 0.10; 
condition x drug: F(1,1) = 2.157, p = 0.15] (Figure 4.2F). In Ctrl mice, ketamine treatment 
had no effect on average immobility time for minutes 3-6 (p = 0.89). In saline-treated mice, 
SD significantly increased depressive-like behavior as measured by average time immobile 
over minutes 3-6 of day 2 of FST (p < 0.001). Ketamine administration prior to SD (SD, K) 
protected the mice against this stress-induced depressive-like behavior (p < 0.01). These 
data indicated that ketamine increases stress-resilience in the FST, and that this effect 
persisted out to at least 3 weeks following a single injection.  
 
Figure 4.2. Ketamine decreases immobility in the forced swim test in stressed mice.
Sal and Ctrl, K mice displayed equal amounts of immobility on day 1 [repeated measures 
ANOVA, drug: F(1,28) = 0.268, p = 0.61; minute: F(1,5) = 22.450, p < 0.0001; drug x minute: 
F(1,5) = 1.189, p = 0.32]. (B) SD, Sal and SD, K mice also displayed equivalent levels of 
immobility on day 1 [repeated measures ANOVA, drug: F(1,26) = 0.693, p = 0.41;
F(1,5) = 19.898, p < 0.0001; drug x minute: F(1,5) = 0.746, p = 0.59]. (
immobility time for minutes 3-
Sal mice [ANOVA, condition: F(1,1) = 2.422, p = 0.13; drug: F(1,1) = 0.004, p
condition x drug: F(1,1) = 0.258, p = 0.61]. (
on day 1, mice were administered day 2 of the FST. Ctrl, Sal and Ctrl, K mice did not differ 
from each other [repeated measures ANOVA, drug: F(1,28) = 0.004,
= 0.362, p < 0.0001; drug x minute: F(1,5) = 0.362, p = 0.87]. (
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 p = 0.95; minute: F(1,5) 
E) SD, K mice exhibited 
 
 (A) Ctrl, 
 minute: 
 = 0.95; 
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significantly less immobility when compared with SD, Sal mice [repeated measures ANOVA, 
drug: F(1,21) = 8.094, p < 0.01; minute: F(1,5) = 6.949, p < 0.0001; drug x minute: F(1,5) = 
0.367, p = 0.87; planned comparisons, p’s = 0.08, 0.04, 0.01, 0.01, 0.02, 0.02 for minutes 1, 2, 
3, 4, 5, and 6, respectively]. (F) For minutes 3-6, there were differences in average 
immobility [ANOVA, condition: F(1, 1) = 6.294, p = 0.02; drug: F(1,1) = 2.789, p = 0.10; 
condition x drug: F(1,1) = 2.157, p = 0.15]. Average immobility time for minutes 3-6 was 
increased in the SD, Sal mice when compared with the Ctrl, Sal mice (p < 0.001). 
Furthermore, the SD, K mice displayed an average immobility time that was less when 
compared with the SD, Sal mice (p < 0.01). (n = 13-15 male mice per group). Error bars 
represent + SEM. * p < 0.05; ** p < 0.01, *** p < 0.001. 
 
Social interaction with a dominant aggressor, is increased by ketamine administration prior 
to social defeat 
Social interaction (SI) is the most robust way of testing the induction of depressive-like 
behavior by SD (Schloesser et al., 2010). Accordingly, following administration of the FST, 
we tested mice in a SI paradigm where the aggressor CD-1 was enclosed under a wire mesh 
cup in an open field box, and the experimental animal had the option to interact with the 
dominant CD-1 or an empty control cup, or to explore the arena (Figure 4.3A). As 
expected, following SD, saline treated mice (SD, Sal) spent significantly more time 
investigating the empty enclosure quadrant when compared with control saline-treated 
mice (Ctrl, Sal) (p = 0.02) (Figure 4.3B). Control mice, either pre-treated with saline or 
ketamine, spent an equivalent amount of time investigating the empty enclosure quadrant 
(p > 0.05). SD, K mice exhibited significantly less time investigating the empty enclosure 
quadrant when compared with SD, Sal mice (p = 0.02). Similarly, SD, K mice exhibited a 
significantly increased willingness to interact with the dominant aggressor CD-1 when 
compared with SD, Sal mice (p < 0.05) (Figure 4.3C). There was an overall effect of SD and 
of ketamine on decreasing the distance traveled during SI, but the interaction was not 
significant [ANOVA, condition: F(1,1) = 11.302, p < 0.01; drug: F(1,1) = 4.391, p = 0.04; 
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condition x drug: F(1,1) = 1.395, p = 0.24] (Figure 4.3D). Furthermore, there was an 
overall effect of SD, but not of ketamine on the velocity during SI [ANOVA, condition: F(1,1) 
= 7.616, p < 0.01; drug: F(1,1) = 0.675, p = 0.68; condition x drug: F(1,1) = 2.093, p = 0.15] 
(Figure 4.3E). These data suggest that SD decreases exploration and willingness to interact 
with the CD-1 aggressor, and that prior ketamine administration protects against this 
deleterious effect of SD stress on social behavior. 
 
 
Figure 4.3. Ketamine protects against the deleterious effects of SD stress on 
interaction. Mice were allowed to explore an open field containing two wire cups, one 
empty and one containing the aggressor CD
each group. (B) Ctrl, Sal and Ctrl, K mice had comparable levels of time spent investigating 
an empty enclosure (p > 0.05). SD, Sal mice spent significantly more time investigating the 
empty enclosure when compared with the Ctrl, Sal mice (p = 0.02). Conversely, SD, K mice 
spent significantly less time investigating the empty enclosure when compared wi
Sal mice (p = 0.02). (C) Ctrl, Sal and Ctrl, K mice spent comparable amounts of time 
investigating a CD-1 mouse (p = 0.17). Conversely, SD, K mice spent considerably more 
time investigating a CD-1 mouse when compared with SD, Sal mice (p < 0.05)
was an overall effect of SD and of ketamine on decreasing the distance traveled during SI, 
but the interaction did not reach significance [ANOVA, condit
drug: F(1,1) = 4.391, p = 0.04; condition x drug: F(1,1) = 1
an overall effect of SD, but not of ketamine on the average velocity [ANOVA, condition: 
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F(1,1) = 7.616, p < 0.01; drug: F(1,1) = 0.675, p = 0.68; condition x drug: F(1,1) = 2.093, p = 
0.15]. (n = 13-15 male mice per group). Error bars represent + SEM. * p < 0.05, ** p < 0.01.  
 
An injection of ketamine prior to social defeat does not impact anxiety-like behavior or 
contextual fear memory  
Having observed a strong protective effect of ketamine in two depression-related 
behaviors, we then examined the effects of ketamine on anxiety and fear-based tests. In 
novelty suppressed feeding (NSF), we found no significant effect of ketamine on the latency 
to feed in either the Ctrl (Mantel-Cox log rank text: p = 0.37) or the SD mice (Mantel-cox log 
rank test: p = 0.75) (Figure 4.4A). In fact, all groups showed similar latencies to feed (p’s > 
0.05) (Figure 4.4B). These data suggest that there was no effect of SD on anxiety, at least as 
measured by NSF.  
 
 
Figure 4.4. Ketamine does not alter anxiety
Ctrl, Sal and Ctrl, K mice had equivalent latencies to approach the food pellet (Mantel
log rank text: p = 0.37). SD, Sal and SD, K mice also had equivalent latencies (Mantel
rank test: p = 0.75). (B) All groups had equivalent average latencies to approach the food 
pellet (p’s > 0.05).  
 
This anxiety-based interpretation is, however, confounded by the fact that, despite having 
comparable body weights before and after SD (p’s >
significantly more weight during the 12 h fast preceding NSF than Ctrl mice (p < 0.0001) 
(Figure 4.5B). Possibly, as a result, SD mice ate more following NSF when com
Ctrl mice (p < 0.01) (Figure 4.5C
metabolism in 129S6/SvEvTac mice.
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-like behavior in NSF. (A) In the NSF paradigm, 
 0.05) (Figure 4.5A), SD mice lost 








Figure 4.5. Social defeat, but not ketamine, alters metabolism.
with social defeat does not impact body weight. Ctrl and SD mice had comparable body 
weights before the start of SD and following SD.  Ketamine did not affect body weight in 
either of these groups. (p’s > 0.05). (
over a 12-hour fast than Ctrl mice (p < 0.0001). (
food in standard housing conditions than Ctrl mice, suggesting that fasting had more of an 
impact on the hunger drive in SD mice than in Ctrl m
per group). Error bars represent 
 
 We observed a significant effect of SD in another anxiety
plus maze (EPM). SD mice spent more time in the closed arms than
[ANOVA, condition: F(1,1) = 23.993, p < 0.0001; drug: F(1,1) = 0.176, p = 0.68; condition x 
drug: F(1,1) = 1.202, p = 0.28]. However, there was no significant effect of ketamine in 
either group (Ctrl, Sal vs. Ctrl, K, p = 0.35; SD, 
effect of ketamine in the EPM is consistent with previous studies 
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+ SEM. ** p < 0.01, *** p < 0.001. 
-related test, the elevated 
 Ctrl mice (
Sal vs SD, K, p = 0.56). The absence of an 





Silva et al., 2010), as it remains to be established if ketamine is as robust an anxiolytic as it 
is an antidepressant (Caddy et al., 2014)
Figure 4.6. Ketamine does not alter anxiety
spent significantly more time in the closed arms when compared with Ctrl mice (p < 0.001). 
Ctrl, Sal and Ctrl, K mice did not differ in the amount of time spent in the closed arms (p = 
0.35). SD, Sal and SD, K mice did not differ in the amount of time spent in the closed arms (p 
= 0.56). (n = 13-15 male mice per group). Error bars represent 
 
 
 Finally, we assessed the impact of SD and prior treatment with ketamine in a 1
shock contextual fear conditioning (CFC) paradigm 
One group previously found that SD increased context
shock CFC paradigm (Yu et al., 2011)
paradigm, as we have previously show
ablation of adult hippocampal neurogenesis 
typically reduced by SD in a C57Bl/6J strain 
experiments, we found no effect of either SD or of ketamine
freezing levels prior to the shock on day 1 of CFC training (
effect on freezing during context exposure in Ctrl mice [repeated measures ANOVA, drug: 
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+ SEM. *** p < 0.001.
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n this 1-shock CFC paradigm to be sensitive to the 
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 administration on baseline 
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0.277, p = 0.84]. Moreover, there was also no effect of prior ketamine administration on 
freezing levels in the SD groups [repeated measures ANOVA, drug: F(1,26) = 0.086, p = 
0.77; minute: F(1,3) = 47.336, p < 0.0001;
4.7B). Though this does not allow us to interpret any stress resilience effect of ketamine, as 
there is no effect of stress to protect against, it does at least demonstrate that a single 
injection of ketamine does not appear to interfere with the ability to form contextual 
memories in mice. 
Figure 4.7. Ketamine does not alter contextual fear conditioning learning.
Ctrl, K mice had comparable levels of freezing before the shock during CFC 
[repeated measures ANOVA, drug: F(1,28) = 0.815, p = 0.37; minute: F(1,2) = 0.896, p = 
0.41; drug x minute: F(1,2) = 0.718, p = 0.49]. SD, Sal and SD, K mice had comparable levels 
of freezing before the shock during CFC training [repeated measures
= 1.152, p = 0.29; minute: F(1,2) = 0.555, p = 0.58; drug x minute: F(1,2) = 1.537, p = 0.23].
(B) Ctrl, Sal and Ctrl, K mice expressed comparable levels of context
measures ANOVA, drug: F(1,28) = 0.046, p = 0.83; m
x minute: F(1,3) = 0.277, p = 0.84]. SD, Sal and SD, K also expressed comparable levels of 
context-elicited fear [repeated measures ANOVA, drug: F(1,26) = 0.086, p = 0.77; minute: 
F(1,3) = 47.336, p < 0.0001; drug x
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The behavioral improvements following an injection of ketamine are not mediated by 
alterations in adult hippocampal neurogenesis 
To determine if the improvement in depressive-like behavior following a single injection of 
ketamine were mediated by an increase in adult hippocampal neurogenesis, we quantified 
the number of Ki67+ and DCX+ cells in the dentate gyrus (DG) (Figure 4.8). There was no 
effect of SD or of ketamine on the average number of Ki67+ cells in the DG [ANOVA, 
condition: F(1,1) = 1.204, p = 0.28; drug: F(1,1) = 0.258, p = 0.62; condition x drug: F(1,1) = 
0.725, p = 0.40] (Figure 4.8A, 4.8B). Furthermore, there was no effect of SD or of ketamine 
on the average number of DCX+ cells in the DG [ANOVA, condition: F(1,1) = 0.409, p = 0.52; 
drug: F(1,1) = 2.622, p = 0.12; condition x drug: F(1,1) = 0.131, p = 0.72] (Figure 4.8C, 
4.8D). These data suggest that the improvements seen in depressive-like behavior 
following a single injection of ketamine administration are not mediated by alterations in 
adult hippocampal neurogenesis and are likely facilitated by changes in other circuits. 
 
 
Figure 4.8. Ketamine-induced improvem
adult hippocampal neurogenesis.
average number of Ki67+ cells [ANOVA, condition: F(1,1) = 1.204, p = 0.28; drug: F(1,1) = 
0.258, p = 0.62; condition x drug: F(1,1) = 0.725, p = 0.40]. (B) Representative image of 
Ki67 immunohistochemistry in the DG
effect of SD or of ketamine on the average number of DCX
= 0.409, p = 0.52; drug: F(1,1) = 2.622, p = 0.12; condition x drug: F(1,1) = 0.131, p = 0.72]. 
(D) Representative image of DCX immunohis
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ent in depressive-like behaviors is not mediated by 
 (A) There was no effect of SD or of ketamine on the 
. The arrows indicate Ki67+ cells. (C) There was no 
+ cells [ANOVA, condition: F(1,1) 




In these experiments, we show that a single injection of ketamine before 
administration of a social defeat (SD) paradigm protected mice against stress-induced 
increased immobility in the forced swim test (FST), a measure of depressive-like behavior. 
Additionally, ketamine protected mice against stress-induced social avoidance of an 
aggressor mouse, even after two weeks of SD. In animal models, stress resilience is defined 
by the absence of the stress-induced increases in the depressive-like and anhedonic 
behaviors seen in susceptible mice. Consistent with the literature definition of stress 
resilience, we found that mice administered ketamine prior to SD were protected from 
developing stress-induced depressive-like behavior as observed in the FST and the social 
interaction (SI) paradigms, but their behavior in anxiety tests and levels of adult 
hippocampal neurogenesis were not significantly impacted.  
These findings demonstrate that ketamine can increase stress resilience. 
Furthermore, a single injection is sufficient to protect against depressive-like behavior, 
even over a period of prolonged stress exposure. Ketamine-induced resilience was robust 
and long lasting—persisting for at least 3 weeks post-injection. It is worth noting that, as 
the half-life of ketamine is only a few hours, ketamine is not on board at any point during 
the 2-week stress paradigm. The term stress resilience is used here to mean the prevention 
of the induction of depressive-like behavior, not just symptom suppression. To our 
knowledge, this is the only study to demonstrate a protective affect of an antidepressant 
that persists significantly beyond drug washout. 
Taken together, these findings raise the possibility that drugs in our existing 
pharmacopeia may be ready for clinical use as resilience-enhancers. This offers a new 
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approach to protecting at-risk populations against stress-induced pathology. Traditionally, 
affective disorders have been treated from a symptom-reduction approach. We currently 
lack the understanding and tools to cure mood and anxiety disorders, so successful 
mitigation of symptoms is considered the best therapeutic outcome. Here, we have 
identified a new phenomenon in which a one-time injection of ketamine is prophylactic 
against subsequent stress-induced psychopathology, not just symptomology. In a similar 
manner, vaccination against viruses and bacteria makes symptom management 
unnecessary by protecting against infection. Because the protective effect of ketamine 
persists beyond its half-life of 2-2.5 h (Idvall et al., 1979), assuming the prophylactic effect 
translates to humans, it is potentially useful as a vaccine-like strategy in at-risk populations 
where high-stress conditions can be predicted. Active combat soldiers offer a good example 
of a predictably at-risk patient population. Administration of ketamine prior to deployment 
may mitigate the emergence of PTSD or other stress-related disorders in a vulnerable 
population. 
The persistent prophylactic effect of ketamine further supports the hypothesis that 
stress resilience is, at least in part, an active process, and not just an absence of 
susceptibility risk-factors. Moreover, the fact that ketamine-induced resilience continues 
after washout, despite chronic SD exposure, demonstrates that resilience can be a self-
maintaining active process. Experimentally, these findings open up a new avenue towards 
dissecting the molecular mechanisms underlying stress resilience by establishing a novel 
model of pharmacological-induced resilience.  
Several cellular, molecular, and circuit-based processes have been implicated in the 
neurobiology of stress resilience, including adult hippocampal neurogenesis, hypothalamic-
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pituitary-adrenal axis (HPA) output, i.e., stress hormones (Lehmann et al., 2013a; Lehmann 
et al., 2013c; Schloesser et al., 2010), ∆FosB expression in the prefrontal cortex (Lehmann 
and Herkenham, 2011; Vialou et al., 2014) and striatum (Donahue et al., 2014), activation 
of the infralimbic cortex and the mesolimbic dopaminergic system (Cao et al., 2010; 
Chaudhury et al., 2013; Covington et al., 2010; Donahue et al., 2014; Krishnan et al., 2007; 
Lehmann and Herkenham, 2011; Vialou et al., 2010a; Vialou et al., 2010b), and 
glutamatergic tone (Vialou et al., 2010b). Additionally, ketamine has been shown induce 
rapid and persistent remodeling of synapses (Li et al., 2010). However, it remains possible 
that ketamine induces stress-resilience through an as-of-yet uncharacterized pathway. 
Interestingly, adult hippocampal neurogenesis does not appear to be mediating this effect, 
as the two paradigms which we have shown to be neurogenesis sensitive, novelty 
suppressed feeding (NSF) and 1-shock contextual fear conditioning (CFC), were not 
affected by this prophylactic treatment with ketamine. 
In summary, these experiments demonstrate that ketamine has a long-lasting 
resilience-enhancing effect and protects against the deleterious effects of chronic stress on 
depressive-like behaviors. How far out this prophylaxis persists—perhaps significantly 
longer than 3 weeks—is as of yet unknown. Whether subsequent injections have a similar, 
increasing, or deleterious effect on stress resilience also has yet to be tested. Most critically, 
it remains to be demonstrated if the resilience-enhancing properties of ketamine we have 
shown here in mice translate to the clinical population. If these effects do translate, 
ketamine may offer a novel, clinic-ready approach to protect and prevent at-risk patients 
















The work in this thesis validates chronic social defeat stress (SD) as a viable model of 
stress-induced cognitive impairment, in addition to the depressive and anxious symptoms 
characteristic of affective disorders. Additionally, we have shown that SD can be used to 
investigate both the rapid-acting antidepressant and long-term resilience-enhancing effects 
of ketamine. In the first study (Chapter 2), we showed that chronic social defeat stress 
induced cognitive deficits in 129S6/SvEvTac (129) mice in two neurogenesis-dependent 
cognitive tasks (Denny et al., 2012): novel object recognition (NOR) and 1-shock contextual 
fear conditioning (CFC). Social defeat also decreased survival of young adult-born neurons 
in the dentate gyrus (DG) of the hippocampus. Knowing that both NOR and 1-shock CFC are 
neurogenesis-dependent, and that SD decreased neurogenesis, we hypothesized that either 
the DG or its downstream target, CA3, may house a cellular correlate of these cognitive 
deficits. 
 Using an ArcCreERT2(+) x R26R-STOP-floxed-EYFP(+/-) (ArcCreERT2) mouse that 
allows for indelible labeling of an activated population of cells in a temporally-restricted 
manner, we labeled the population of cells activated during training in 1-shock CFC. When 
we compared this population to the population of cells activated during retrieval, mice with 
impairment in 1-shock CFC recall, i.e., the SD mice, showed less cellular reactivation in CA3 
than the non-defeated mice who successfully recalled the training context. There was no 
difference in reactivation in the DG, or in total number of cells activated in during training 
or re-exposure in either region. Taken together, these data establish decreased reactivation 
in CA3 as a cellular correlate of stress-induced cognitive impairment. Not only does this 
further support the hypothesis that CA3 is responsible for the strength of a CFC fear 
 104 
memory trace (Denny et al., 2014), it also suggests that interventions targeting the 
hippocampus may ameliorate the cognitive symptoms of affective disorders. Altogether, 
the findings in Chapter 2 argue for increased research on the cognitive dimensions of 
psychiatric disorders. 
 In the second study (Chapter 3), we utilized this validated SD model of stress-
induced psychopathology to explore the effects of ketamine as a rapid-acting 
antidepressant (AD). Most of the published studies examining the AD effect of ketamine in 
mice have been done at baseline in strains that do not show a response to classical 
antidepressant treatment unless they are chronically stressed. We show here that ketamine 
has a modest antidepressant effect in 129 mice following chronic stress. The data from 
Chapter 3, in combination with a review of the literature, suggest that ketamine 
administration in mice has yet to be optimized to produce a robust antidepressant effect. 
Additionally, because of its predictive power, forced swim tests conducted within 24 hours 
of drug administration are insufficient to establish an antidepressant effect. Until further 
work is done to improve the robustness of murine ketamine antidepressant models, 
molecular and cellular studies on ketamine conducted in mice—especially those showing 
negative results—should be considered with a high degree of scrutiny. 
 Antithetically, we show in Chapter 4 that ketamine has a robust long-term 
protective effect in mice. A single subanesthetic injection of ketamine prevented mice from 
developing chronic stress-induced depressive-like behavior even out to three weeks post-
washout. This supports the hypothesis that stress resilience is not a passive process, but an 
active self-maintaining one (Russo et al., 2012). The ketamine-pretreatment model 
presented in Chapter 4 establishes a novel model for the study of stress resilience. 
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Additionally, as opposed to the work presented in Chapter 3, where the antidepressant 
effect in mice lags behind what is seen in the clinic, ketamine’s prophylactic effect in mice 
pre-dates its clinical exploration. It remains to be seen if ketamine’s protective effect 
translates to humans. If it does, however, the implications are far-reaching. Current 
treatment paradigms for psychiatric disorders are palliative, not preventative. If protective 
in patients, ketamine would be the first known prophylactic against psychiatric disorders. 
Regardless of the efficacy of ketamine in humans, the experiments in Chapter 4 make a 
strong argument that resilience-enhancing drugs are a feasible clinical goal. 
 Taken together, these three studies 1) identify a cellular correlate of a stress-
induced cognitive deficit; 2) demonstrate that mice are not yet an optimized model for 
examining the mechanism of action of ketamine as an antidepressant; and 3) establish 
ketamine as the first drug known to have stress resilience-enhancing properties. In many 
ways, these studies are reflective of a field-wide departure from the past 50 years of 
depression and antidepressant research, which focused primarily on depressive and 
anxious symptoms and chronic treatment with classical antidepressants. In the next few 
years, work exploring the cognitive aspects of psychiatric disorders, rapid-acting 
antidepressants, and stress resilience promises to contribute significantly to our 
understanding of the etiology and pathophysiology of affective disorders and, ideally, lead 






Implications and Considerations 
Considerations for the study of the cognitive symptoms of psychiatric disorders 
Though diagnosis and treatment traditionally focuses on resolving the depressive, anxious, 
and anhedonic symptoms of affective disorders, cognitive dysfunction is reported as 
commonly and often as equally disruptive to quality of life as other symptoms (Castaneda 
et al., 2010; Hollon et al., 2006; Pandina et al., 2009). Cognitive symptoms appear not to be 
secondary to mood symptoms and, in fact, are considered one of the primary diagnostic 
symptoms for MDD in the DSM-V (APA, 2013). Some studies suggest that cognitive deficits 
persist in non-medicated remitted patients (Nagane et al., 2014; Weiland-Fiedler et al., 
2004), further supporting the hypothesis that cognitive impairment in psychiatric 
disorders may be independent of affective state. And as cognition has not been the primary 
focus in the development of therapeutic interventions, cognitive deficits are often not 
resolved even with antidepressant intervention that successfully ameliorates affective 
symptoms (Fava et al., 2006; Hasselbalch et al., 2012). In fact, some antidepressants can 
induce or worsen cognitive deficits in some patients (Amado-Boccara et al., 1995; Nagane 
et al., 2014; Schmitt et al., 2002) and persistence of cognitive symptoms after treatment is 
predictive of poorer outcomes (Jaeger et al., 2006; McCall and Dunn, 2003). Thus, the 
cognitive dysfunction aspects of mood disorders should be treated as potentially having 
distinct mechanisms from those of the mood symptoms. 
Both when studying the mechanisms underlying stress-induced psychopathology 
and designing new therapeutic interventions, dedicated attention should be paid to 
cognitive deficits. We have shown in this thesis that chronic social defeat stress is a valid 
model for examining hippocampus-dependent cognitive tasks and identifying novel cellular 
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targets for intervention, but this model and other animal models of affective disorders have 
yet to be fully characterized across the spectrum of cognitive impairment. By using these 
animal models to dissect stress-induced cognitive impairments, we may be able to identify 
drugs that directly address the cognitive symptoms of affective disorders.  
 
Considerations for the study of rapid-acting antidepressants 
Though ketamine was first reported as having antidepressant properties almost forty years 
ago—less than five years after it received FDA approval (Bovill et al., 1971; Sofia and 
Harakal, 1975)—its rapid antidepressant effect was only identified in 2000 (Berman et al., 
2000), and only recently has it begun to be systematically studied both in the clinic and in 
animal models. Ketamine is not the only drug to garner recent attention as a rapid-acting 
antidepressant; other glutamatergic drugs are being studied (Krystal et al., 2013), as well 
as the antimuscarinic agent, scopolamine (Drevets and Furey, 2010; Furey and Drevets, 
2006), and 5-HT4 agonists (Vidal et al., 2013).  
Though work on rapid-acting antidepressants has increased exponentially since 
2000, the field is still young. In mouse models, even ketamine dose titration has yet to be 
systematically optimized and strain responses have yet to be fully characterized. In many 
ways, the rapid-acting antidepressant field builds on and benefits from the many years of 
experimental work done with classical antidepressants. In other ways, experiments on 
rapid-acting antidepressants are hindered by our pre-existing conceptions based on 
classical antidepressant research. For example, the forced swim test (FST) is the 
assessment most commonly reported in the rapid-antidepressant mouse literature. 
Unfortunately, the major confound of FST as both a test of depressive behavior and 
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predictive of a drug’s antidepressant properties has been mostly overlooked in 
experimental design.  
 To reiterate, in order to study the cellular and molecular mechanisms underlying 
the rapid-onset antidepressant effect of drugs like ketamine, it is essential to first establish 
an antidepressant effect in a given model. Acute administration of both ketamine and 
fluoxetine decrease immobility in the forced swim test. It is known, however, that an acute 
dose of fluoxetine is insufficient to have an antidepressant effect; chronic administration is 
required. It is not assumed that an acute effect of fluoxetine in FST indicates an onset of 
therapeutic efficacy. In the case of classical antidepressants, due to the built-in constraint of 
delayed onset of efficacy, the acute predictive validity of FST is easily distinguished from 
face validity. For rapid-acting agents, however, because the time-course of antidepressant 
efficacy is contemporaneous with that of the predictive response in FST, predictive validity 
and face validity are more easily confounded. This is not to say that FST cannot be used to 
demonstrate the antidepressant effect of ketamine, especially when the test is 
administered several days after drug washout. It is simply to argue that only showing an 
effect in FST within 24 hours of ketamine administration is insufficient to establish an 
antidepressant effect. Therefore, additional behavioral tests are needed to assure that 
ketamine has produced a true antidepressant response in any given model or strain. 
 
The role of neurogenesis in the antidepressant and prophylactic effects of ketamine 
The hippocampus has recently been identified as a potential modulator of ketamine’s 
rapid-acting antidepressant effects (Autry et al., 2011), but the relative contribution of 
adult hippocampal neurogenesis has yet to be explored. Neurogenesis has been heavily 
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implicated in the mechanism of action of other antidepressant therapies (SSRIs, exercise, 
etc.). Because of the time-course, however, it seems unlikely that increased hippocampal 
neurogenesis, at least in the traditional sense, is required for the rapid-onset 
antidepressant effects of ketamine. For the mechanism of action (MOA) of classical 
antidepressants, it is thought that these drugs increase the number of functionally 
incorporated 4-6 week-old adult-born neurons in the hippocampus by increasing survival 
or proliferation rates (Blanchard et al., 2001; Lacefield et al., 2012; Malberg et al., 2000). In 
fact, the delay in therapeutic onset following chronic SSRI administration has been 
putatively attributed to the time it takes for newborn cells to reach this critical age. 
Therefore, it seems unlikely that ketamine’s rapid antidepressant effect is mediated 
through proliferation or increased survival of newborn neurons.  
However, it is the properties of these 4-6 week-old granule cells, and not their age 
per se, that implicate them in the MOA of classical antidepressants. One group has found 
preliminary evidence that a single subanesthetic dose of ketamine can induce rapid 
maturation and functional incorporation of newborn neurons in the dentate within 2 hours 
of injection (Carter et al., 2012). Researchers have also recently identified dematuration, in 
which older cells re-express proteins associated with earlier developmental stages, as 
another process that influences the neurogenic niche (Kobayashi et al., 2010). It is plausible 
that ketamine could work in a neurogenesis-dependent manner by influencing the 
maturation state of young adult-born neurons in the hippocampus, thereby altering the 
behavior of these young neurons that are already functionally integrated into the circuit. 
We hypothesize that the antidepressant effects of ketamine may be neurogenesis-
dependent and, if so, that this is likely due to changes in maturation state of already 
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existing adult-born neurons, and not changes in proliferation or long-term survival of 
newly generated cells. 
 Increases in survival and proliferation, in conjunction with rapid maturation and 
dematuration, may play a direct role in the long-term self-maintaining protective effects of 
ketamine. As we have previously shown that hippocampal neurogenesis is required for 
adrenalectomy-induced stress resilience (Lehmann et al., 2013a), the requirement of an 
intact neurogenic niche for ketamine-induced stress resilience in particular warrants 
further study.  
 
Future Directions: Rescue of stress-induced cognitive deficits 
Optogenetic rescue of SD 1-shock deficit by re-activation of training cells in CA3 
The ArcCreERT2 mouse described in Chapter 2 can also be used to assess functional aspects 
of memory traces when paired with floxed light-activated channels or DREADDs (Designer 
Receptors Exclusively Activated by Designer Drugs). Our lab has previously shown that 
inactivating the cellular memory trace associated with CFC in CA3 blocks expression of 
learned fear (Denny et al., 2014). This demonstrates that reactivation in CA3 is necessary 
for fear expression. It is possible that artificial reactivation of cells in CA3 may be sufficient 
to rescue the chronic stress-induced 1-shock deficit.  
In order to test this, ArcCreERT2 mice will be crossed with R26R-STOP-floxed-
channelrhodopsin (ChR2)-EYFP mice (Figure 5.1). Channelrhodopsin is a light-gated ion 
channel that, when activated by 470 nm light, allows cations to flow into the cell, causing 
depolarization and firing of neurons (Smedemark-Margulies and Trapani, 2013). 
 
Figure 5.1. ArcCreERT2 x R26R
 
 
ArcCreT2 (+) x ChR2-eYFP (Cre+) and ArcCre
mice will be bilaterally implanted with chronically dwelling optical fibers (200 mm core, 
0.37 numerical aperture multimode fiber, ThorLabs) above CA3 (
AP, -1.6 mm DV) and allowed two weeks to recover prior to undergoing chronic social 
defeat stress or remaining in control housing. Following two weeks of SD, mice will be 
administered tamoxifen (TAM) 5 hours prior to CFC 1
weeks for sufficient channelrhodopsin protein accumulation to permit for exogenous 
activation of the cells. Two weeks after the initial CFC training, mice will be connected via 
patch cord to a 473 nm laser diode (OEM laser systems) for optical stimulation, as 
previously described (Kheirbek et al., 2013)
Freezing will be assessed for 3 minutes with the light OFF, then freezing will be assessed 
for a second 3 minute epoch with the light ON. We hypothesize that exogenous activation of 
the cells activated during learning will increase freezing in Cre+ SD mice, rescuing the 
stress-induced deficit in recall. One hour following simulation, mice will be sacrificed and 
brains collected for subsequent ChR2
predict that Cre+ SD mice receiving optical stimulation will show a higher percentage of 
reactivated (YFP+/c-fos+) cells than Cre
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-CAG-STOP-floxed-ChR2-eYFP mice.  
T2 (-) x ChR2-eYFP (Cre-) littermate control 
+/-1.7 mm ML, 
-shock training, and then allowed two 
, and returned to the training chamber. 
-eYFP and immediate early gene (IEG) analysis. 





increased reactivation will correlate with improved fear expression. Beyond just housing a 
cellular correlate of stress-induced cognitive impairment, these experiments would identify 
whether CA3 is a viable therapeutic target for ameliorating cognitive deficits in psychiatric 
disorders.  
 
Future Directions: Use of ketamine as a rapid-acting antidepressant in mice 
Dose titration  
Though 30 mg/kg ketamine is sufficient to get a modest antidepressant (AD) effect in 129 
mice, it is clear from the effect size we see in our model compared to the robust effect 
reported clinically that this may not be the optimal AD dose for mice. Doses used in the 
mouse literature vary from as low as .5 mg/kg (Maeng et al., 2008) to as high as 360 mg/kg 
(Bechtholt-Gompf et al., 2011), and more extensive systematic dose titration studies are 
desperately needed to standardize the field. Moreover, as strains differ greatly in their 
response to different doses of ketamine, as shown in Chapter 3, a dose optimized in one 
strain cannot be assumed to translate directly for use in another. Of additional 
consideration is the fact that, clinically, ketamine is administered gradually over several 
hours, not in a single bolus (Murrough et al., 2013a; Murrough et al., 2013b; Zarate et al., 
2006). It is possible that an administration method that more closely recapitulates the 
clinical approach will produce greater antidepressant effects in mice.  
This is not work we propose to do in our lab, but in the absence of standardization, 
it is a challenge to interpret many of the findings in the rapid-acting antidepressant 
literature. Therefore it is essential for the advancement of the field that more rigorous dose 
titration studies be conducted in multiple labs.  
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Local infusion: Identifying brain regions sufficient for rapid-antidepressant effects 
Many groups have postulated that the nucleus accumbens, ventral tegmental area, 
prefrontal cortex, and hippocampus, among other regions, are involved in ketamine’s 
rapid-onset antidepressant effect (Cao et al., 2010; Chaudhury et al., 2013; Covington et al., 
2010; Donahue et al., 2014; Krishnan et al., 2007; Lehmann and Herkenham, 2011; Vialou 
et al., 2014; Vialou et al., 2010a; Vialou et al., 2010b). Because the effects of ketamine do not 
require multiple doses, local infusion of ketamine into specific brain regions could be used 
to identify which of those regions are sufficient for its rapid antidepressant effect. Either 
cannulation and subsequent infusion or stereotactic Hamilton syringe infusion would serve 
to this end. As ketamine/xylazine could not be used for anesthesia for obvious reasons, and 
as isoflurane has also been identified as putatively having rapid-antidepressant effects 
(Rantamaki et al., 2013; Weeks et al., 2013), special consideration would need to be given 
to anesthetic selection for surgical use. We would recommend the use of pentobaritol 
sodium, based on previous x-irradiation experiments (Denny et al., 2012).  
Local infusion of ketamine followed by antidepressant behavioral testing would 
provide invaluable insight into which brain regions are sufficient for the rapid-onset 
antidepressant effect of ketamine. Identifying these regions will inform development of 
more-targeted rapid-acting therapeutics, as well contribute to our understanding of the 





Future Directions: Ketamine as a resilience-enhancer 
Further characterization of the protective effect of ketamine in the SD model 
Though we have shown in Chapter 4 that a single dose of subanesthetic ketamine is 
sufficient for robust protection against stress-induced depressive-like behaviors, as seen in 
FST and social interaction test, whether ketamine is protective against stress-induced 
anhedonia and cognitive deficits has yet to be established. To test the effect of prior 
ketamine on anhedonia, we propose to run mice in sucrose preference (SPT) (Papp et al., 
1991) and urine scent marking open field (USM) tests following drug administration and 
two weeks of SD.  
In SPT, mice are trained overnight for two subsequent nights with two water 
bottles: one containing normal drinking water, the other containing 2% sucrose solution. 
The position of the bottles is switched on the second day. Water and sucrose consumption 
is recorded to confirm that the mice have learned that one bottle contains sucrose. On the 
third day, mice are food and water deprived then placed in a novel cage for 1 hour for 
sucrose consumption assessment. Mice are given the choice between normal drinking 
water and a 1% sucrose solution. We have found that these conditions are sufficient to 
identify differences in sucrose preference following SD. SD mice consume less sucrose than 
control-housed mice (data not shown), a measure of anhedonia. We hypothesize that 
ketamine administration prior to SD will protect the mice against stress-induced anhedonia 
in SPT. 
 Urine scent marking (USM) is a relatively new test that examines hedonically 
motivated social behavior (Lehmann et al., 2013b). In USM, a spot of urine collected from a 
proestrus female is placed on a sheet of paper in an open field arena, and males are allowed 
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to explore the arena for 10 min. Time sniffing on the female urine spot as well as male scent 
marking (which can be visualized using ninhydrin or UV light) are quantified. Socially 
defeated mice show significantly decreased sniffing and scent marking near the female 
urine spot (Lehmann et al., 2013b). We hypothesize that ketamine administration prior to 
SD will rescue this stress-induced increase in anhedonic behavior. 
 In our experiments in Chapter 2, we saw significant cognitive impairment in SD mice 
in both novel object recognition (NOR) and 1-shock contextual fear conditioning (CFC). 
Though we did not observe a 1-shock deficit in either set of ketamine experiments 
(Chapters 3 and 4), this is most likely because there was not a multi-day delay between 
training and context re-exposure in these experiments. We propose to test the effect of 
administering ketamine prior to SD on stress-induced cognitive impairment by testing the 
mice in 1-shock CFC with a five day interval before re-exposure to the training context (i.e., 
the paradigm described in Chapter 2) and in NOR. We hypothesize that ketamine will 
protect the mice against SD-induced cognitive impairment. 
 In addition to behavioral characterization, we propose to characterize the effect of 
prior ketamine on stress-induced peripheral changes. As seen in Chapter 4, ketamine prior 
to SD did not prevent stress-induced changes in metabolism. As prior ketamine did protect 
against depressive-like behavior, this finding suggests that peripheral metabolic changes 
are not causally involved in the pathophysiology of depressive behavior. To further 
establish what peripheral changes ketamine does or does not mitigate, we will assay 
baseline and stress levels of corticosterone and testosterone by enzyme immunoassay, as 
well as characterize the peripheral immune cell profile by complete blood count (CBC) in 
stressed and control mice with or without prior ketamine treatment. Identifying which 
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peripheral changes are not prevented by prior ketamine treatment will provide insight into 
whether the pathophysiology of stress-induced peripheral changes is independent of 
persistent depressive-like behavior. 
 Additionally, we will investigate neuronal changes induced by prior ketamine 
administration. Specifically, we will quantify ∆FosB levels in the prefrontal cortex, as both 
∆FosB and the infralimbic cortex have been implicated in other forms of stress resilience 
(Berton et al., 2007; Covington et al., 2010; Donahue et al., 2014; Lehmann and Herkenham, 
2011; Muschamp et al., 2012; Ohnishi et al., 2011; Vialou et al., 2010b). We will also 
examine the effects of prior ketamine administration on hippocampal neuronal survival, 
which has been implicated over proliferation in the beneficial effects of antidepressant 
interventions (Lehmann et al., 2013a; Schloesser et al., 2010), by administering BrdU 4 
weeks prior to sacrifice (see Chapter 2 for methods). Identifying changes in these cellular 
and molecular pathways will offer insight into possible mechanisms underlying ketamine’s 
prophylactic effect against stress. 
 Perhaps most importantly, we also propose to characterize the duration of 
ketamine’s protective effect. We have shown that a single injection has a robust self-
maintaining effect that lasts out to 3 weeks. Whether this effect persists significantly longer 
than 3 weeks—out to 6 weeks, 3 months, or even a year or beyond—has yet to be tested. 
The duration of this prophylactic effect has significant implications for the clinical utility of 
ketamine as a resilience-enhancer. If the effect lasts out to several months or even a year, a 
single injection could be administered prophylactically in many cases of possible, but 
unpredictable, stress exposure. If the effect only lasts for 3 weeks, ketamine’s protective 
utility is limited to cases in which stressor onset can be relatively accurately predicted (e.g., 
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high-risk short-term outpost deployment in active-duty soldiers). In addition to the 
duration of the effects of a single prophylactic dose of ketamine, it is essential to identify 
whether subsequent doses augment, sustain, or decrease the resilience-enhancing effect of 
a single injection. 
 Taken together, these experiments would significantly illuminate the resilience-
enhancing properties of ketamine, as well as elucidate the cellular and molecular 
mechanisms underlying stress resilience. 
  
Translation: Other stress paradigms 
It is essential to demonstrate that the protective effect of ketamine can be recapitulated in 
other stress paradigms. Learned helplessness (LH) offers a good secondary model, as 
ketamine has already been established as an antidepressant agent in this paradigm (Autry 
et al., 2011; Beurel et al., 2011; Maeng et al., 2008).  
Though ketamine after LH training has been shown to rescue learned helplessness, 
whether ketamine is protective if administered prior to training has yet to be explored. In 
order to test the protective effect of ketamine in this model, ketamine will be administered 
either 1 week or 3 weeks prior to LH training. During training, mice will be placed in the 
shock chamber and allowed to habituate for 3 minutes. Following the habituation period, 
mice will receive 60 inescapable 0.6 mA shocks of 3 sec average varied duration, with a 15 
sec average varied inter-shock interval. Forty-eight hours post-induction, mice will be 
returned to the LH chamber for assessment of depressive-like behavior. Mice will undergo 
30 trials in which they will receive one 0.3 mA shock per trial. A doorway will open 
allowing the mouse to escape the shock at the beginning of and remain open for the 
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duration of each trial. If the mouse crosses through the doorway, the shock will stop and 
the trial will end. If the mouse does not leave the shock chamber (i.e., displays learned 
helplessness), the shock will continue for the total trial duration of 20 sec. Latency to 
escape over the last 20 trials will be measured to assess depressive-like helpless behavior. 
We hypothesize that ketamine prior to LH training will protect mice from developing 
learned helplessness. 
 
Exploration of the resilience-enhancing potential of other antidepressant agents 
Chronic antidepressant treatment is often referred to colloquially as conferring stress 
resilience, but whether classical antidepressants truly enhance resilience or simply 
suppress symptom expression is somewhat unclear. Moreover, whether classical 
antidepressants have resilience-enhancing potential after washout has yet to be directly 
tested. Clinically, there is reason to suspect that these drugs do not increase stress 
resilience, as classical antidepressants are actually known to increase the risk of relapse if 
treatment is discontinued shortly after the initial antidepressant response (Shelton, 2001). 
Thus we hypothesize that classical antidepressants, such as fluoxetine, will not induce 
resilience unless they are concurrently administered with stress exposure.  
In order to test this hypothesis, mice will be administered an SSRI with a shorter 
half-life than fluoxetine, such as sertraline, for four weeks prior to chronic social defeat 
stress. In the first experiment, SSRI treatment will continue for the duration of SD. 
Following two weeks of SD, drug administration will be discontinued and mice will be 
undergo a week-long drug washout period prior to behavioral testing. In the second 
experiment, mice will be given four weeks of chronic non-fluoxetine SSRI treatment prior 
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to SD, but treatment will be stopped a week before the commencement of SD to allow for 
washout. Following two weeks of SD, mice will be tested in depression and anxiety tests to 
assess if prior SSRI treatment enhances resilience. 
Taken together, these experiments will determine if ketamine is unique in its ability 
to induce long-term self-maintaining stress resilience, or if other known antidepressants 
have similar, hitherto unidentified, resilience-enhancing properties. 
 
Translation: Clinical trials 
Most importantly, experiments need to be conducted in at-risk patients to determine if 
prior ketamine treatment can protect humans against stress-induced psychopathology. A 
cohort of predictably at-risk healthy individuals, such as active-duty soldiers, would be 
required for these studies. If ketamine is in fact prophylactic in humans, subsequent studies 
would be needed to identify optimal dose, timing, and frequency of administration.  
 
Concluding Remarks 
Though we have examined several aspects of stress-related psychopathology and 
treatment in this thesis, by far the most notable finding is that ketamine has the potential to 
increase stress resilience. This finding opens up two important avenues of research. First, it 
establishes a new model of stress resilience, and the only model of drug-induced resilience, 
which can be used to study the biological mechanisms underlying stress resilience. Second, 
this finding establishes that resilience-enhancing drugs are not only feasible, but that some 
of them may already be clinic-ready. Moreover, if ketamine’s ability to induce long-term, 
self-maintaining resilience translates to humans, it could be used as a ‘vaccine’ against 
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stress-induced psychiatric disorders—a possible goal of pharmacotherapy not previously 
considered. Taken together, the findings presented in this thesis represent only a small first 
step in the development of resilience-enhancing drugs, but one that, in the long term, may 
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